Document:

EX-10.1

 Exhibit 10.1 

SCHRÖDINGER, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 TABLE OF CONTENTS 

 

									
	 	 	 	 	 	  	Page	 
			
	 1.
	 	 Definitions
	  	 	1	 
			
	 2.
	 	 Registration Rights
	  	 	6	 
		 	 2.1
	 	 Demand Registration
	  	 	6	 
		 	 2.2
	 	 Company Registration
	  	 	7	 
		 	 2.3
	 	 Underwriting Requirements
	  	 	8	 
		 	 2.4
	 	 Obligations of the Company
	  	 	9	 
		 	 2.5
	 	 Furnish Information
	  	 	10	 
		 	 2.6
	 	 Expenses of Registration
	  	 	11	 
		 	 2.7
	 	 Delay of Registration
	  	 	11	 
		 	 2.8
	 	 Indemnification
	  	 	11	 
		 	 2.9
	 	 Reports Under Exchange Act
	  	 	13	 
		 	 2.10
	 	 Limitations on Subsequent Registration Rights
	  	 	14	 
		 	 2.11
	 	 “Market Stand off” Agreement
	  	 	14	 
		 	 2.12
	 	 Restrictions on Transfer
	  	 	15	 
		 	 2.13
	 	 Termination of Registration Rights
	  	 	16	 
			
	 3.
	 	 Information and Observer Rights
	  	 	16	 
		 	 3.1
	 	 Delivery of Financial Statements
	  	 	16	 
		 	 3.2
	 	 Inspection
	  	 	17	 
		 	 3.3
	 	 Observer Rights; Board Materials
	  	 	17	 
		 	 3.4
	 	 Termination of Information and Observer Rights
	  	 	18	 
		 	 3.5
	 	 Confidentiality
	  	 	18	 
			
	 4.
	 	 Rights to Future Stock Issuances
	  	 	20	 
		 	 4.1
	 	 Right of First Offer
	  	 	20	 
		 	 4.2
	 	 Termination
	  	 	21	 
			
	 5.
	 	 Additional Covenants
	  	 	21	 
		 	 5.1
	 	 Employee Agreements
	  	 	21	 
		 	 5.2
	 	 Employee Stock
	  	 	21	 
		 	 5.3
	 	 Matters Requiring Investor Director Approval
	  	 	22	 
		 	 5.4
	 	 Affirmative Obligations of the Company
	  	 	22	 
		 	 5.5
	 	 Negative Obligations
	  	 	23	 
		 	 5.6
	 	 Cooperation with the Trust
	  	 	24	 
		 	 5.7
	 	 Termination of Covenants
	  	 	24	 
			
	 6.
	 	 Miscellaneous
	  	 	24	 
		 	 6.1
	 	 Successors and Assigns
	  	 	24	 
		 	 6.2
	 	 Governing Law
	  	 	25	 
		 	 6.3
	 	 Counterparts; Facsimile
	  	 	25	 
		 	 6.4
	 	 Titles and Subtitles
	  	 	25	 
		 	 6.5
	 	 Notices
	  	 	25	 
		 	 6.6
	 	 Amendments and Waivers
	  	 	26	 
		 	 6.7
	 	 Severability
	  	 	26	 
		 	 6.8
	 	 Aggregation of Stock
	  	 	27	 

  
 i 

									
	     
	 	 6.9
	 	 Additional Investors
	  	 	27	 
		 	 6.10
	 	 Entire Agreement
	  	 	27	 
		 	 6.11
	 	 Limited Permission for a Party to Seek Specific Performance
	  	 	27	 
		 	 6.12
	 	 Dispute Resolution
	  	 	28	 
		 	 6.13
	 	 Delays or Omissions
	  	 	30	 
		 	 6.14
	 	 Acknowledgment
	  	 	30	 
		 	 6.15
	 	 No Implied Limitation
	  	 	30	 
		 	 6.16
	 	 No Obligation to Cause Actions of Other Entities
	  	 	30	 

  

					
	 Schedule A
	 	—	  	Schedule of Investors
			
	 Exhibit A
	 	—	  	Form of Employment Agreement

  
 ii 

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 9th day of November, 2018, by and among Schrödinger, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is
referred to in this Agreement as an “Investor” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes party to this Agreement in accordance with Section 6.9 hereof. 

RECITALS 
 WHEREAS,
certain of the Investors (the “Existing Investors”) hold shares of the Company’s Preferred Stock and/or shares of Common Stock issued upon conversion thereof and possess registration rights, information rights, rights of first
offer, and other rights pursuant to an Amended and Restated Investors’ Rights Agreement dated as of June 15, 2015 between the Company and such Investors (as amended to date, the “Prior Agreement”); 

WHEREAS, the undersigned Existing Investors desire to amend and restate the Prior Agreement in its entirety and to accept the rights
created pursuant to this Agreement in lieu of the rights granted to them in the Prior Agreement; and 
 WHEREAS, certain of the
Investors and the Company are parties to a Series E Preferred Stock Purchase Agreement of even date herewith, and such agreement conditions such Investors’ obligations upon the execution and delivery of this Agreement by such Investors, the
Company and a group of Existing Investors that has the ability, when considered together with the Company, to amend and restate the Prior Agreement in the manner set forth herein; 

NOW, THEREFORE, the Company, the undersigned Existing Investors, who represent a group of Existing Investors that, together with the
Company, has the ability to amend and restate the Prior Agreement in the manner set forth herein, hereby agree that the Prior Agreement shall be amended and restated in its entirety by the execution of this Agreement, and the parties hereto further
agree as follows: 
 1. Definitions. For purposes of this Agreement: 

“Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled
by, or is under common control with such Person, including any general partner, managing member, officer or director of such Person or any venture capital or other private investment fund now or hereafter existing that is controlled by one or more
general partners or managing members of, or shares the same management company with, such Person. Notwithstanding the foregoing, (x) no DESCO Group Entity shall be deemed to be an Affiliate of David E. Shaw or D. E. Shaw Technology Development,
LLC, and (y) for purposes of each of Sections 2.3(c), 6.1(b)(1), and 6.8 below, (1) neither D. E. Shaw & Co., L.P. nor D. E. Shaw Valence Portfolios, L.L.C. shall be deemed to be an Affiliate of either David
E. Shaw or D. E. Shaw Technology Development, LLC, and (2) neither D. E. Shaw & Co., L.P. nor D. E. Shaw Valence Portfolios, L.L.C. shall be deemed to be an Affiliate of the other. 

 “Cascade” means Cascade Investment, L.L.C. 

“Common Stock” means shares of the Company’s common stock, par value $0.01 per share. 

“Damages” means any loss, damage, or liability (joint or several) to which a party hereto becomes subject under the
Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material
fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material
fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act,
any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

“Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each case,
directly or indirectly), Common Stock, including options and warrants. 
 “DESCO Group Entity” means an investment fund
(i) to which either D.E. Shaw & Co., L.P. or D.E. Shaw & Co., L.L.C. provides discretionary or non-discretionary investment advisory services, whether through a managing member, a
general partner, or an investment adviser, and (ii) that has investors that are not Affiliates of David E. Shaw. 
 “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 

“Excluded Registration” means a registration of the securities of the Company and/or of a subsidiary of the Company
(i) relating to the sale of such securities to employees of the Company and/or of a subsidiary of the Company pursuant to a stock option, stock purchase, or similar plan; (ii) relating to an SEC Rule 145 transaction; (iii) on any form
that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) in which the only Common Stock being registered is Common Stock
issuable upon conversion of debt securities that are also being registered. 
 “Form
S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

“Form S-3” means such form under the Securities Act as in effect on the date hereof
or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

“GAAP” means generally accepted accounting principles in the United States. 

  
 2 

 “Governmental Authority” means any domestic or foreign nation, government,
state or other political subdivision thereof, any entity legally exercising executive, legislative, judicial, regulatory, or administrative functions of or pertaining to government, including any self-regulatory authority (such as a stock or option
exchange or securities self-regulatory organization), governmental authority, agency, commission, department, board, or instrumentality, and any court or administrative tribunal of competent jurisdiction. 

“Holder” means any holder of Registrable Securities who is a party to this Agreement. 

“Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law,
son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein. 

“Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement. 

“IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act. 

“Key Employee” means any executive-level employee of the Company (including division director and vice president-level
positions). 
 “Knowledge,” including the phrase “to the Company’s Knowledge,” shall mean the actual
knowledge of each of Ramy Farid, Jenny Herman, Jennifer Daniel and Yvonne Tran (for so long as such named individuals are providing services to the Company), after having made reasonably diligent inquiries internal to the Company with respect to the
matter at hand. 
 “Major Investor” means (i) any Investor that, individually or together with such Investor’s
Affiliates, holds at least 15,902,140 shares of Preferred Stock (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof); (ii) Deerfield Private Design Fund IV, L.P.
(“Deerfield”) for so long as Deerfield holds at least seventy percent (70%) of the shares of Series E Preferred Stock originally sold to it under the Purchase Agreement (as adjusted for any stock split, stock dividend, combination
or other recapitalization or reclassification effected after the date hereof); (iii) WuXi PharmaTech Healthcare Fund I L.P. (“WuXi”) for so long as WuXi holds all of the shares of Series E Preferred Stock originally sold to it under
the Purchase Agreement (as adjusted for any stock split, stock dividend, combination or other recapitalization or reclassification effected after the date hereof); (iv) Qiming Venture Partners VI, L.P. and Qiming Managing Directors Fund VI, L.P.
(collectively, “Qiming”) for so long as Qiming holds all of the shares of Series E Preferred Stock originally sold to it under the Purchase Agreement (as adjusted for any stock split, stock dividend, combination or other
recapitalization or reclassification effected after the date hereof); and (v) Baron Growth Fund (“Baron”) for so long as Baron holds all of the shares of Series E Preferred Stock originally sold to it under the Purchase
Agreement (as adjusted for any stock split, stock dividend, combination or other recapitalization or reclassification effected after the date hereof). For the avoidance of any doubt, in no event shall Scott Becker be deemed a Major Investor. 

  
 3 

 “New Securities” means, collectively, equity securities of the Company
issued by the Company after the date hereof, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable
into or exercisable for such equity securities. 
 “Non-Voting Common Stock” means
shares of the Company’s non-voting common stock, par value $0.01 per share. 

“Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity. 

“Preferred Stock” means, collectively, shares of the Company’s Series A Preferred Stock, Series B Preferred Stock,
Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock. 
 “Purchase Agreement” means that
certain Series E Preferred Stock Purchase Agreement by and among the Company and certain of the Investors, dated as of the date hereof. 

“Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock held by
the Investors; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of Non-Voting Common Stock or any other securities of the Company,
acquired by the Investors after the date hereof and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or
in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any such Common Stock that would otherwise constitute Registrable Securities but that is sold by a Person in a
transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes of Section 2 any shares for which registration rights have
terminated pursuant to Section 2.13 of this Agreement. The number of Registrable Securities outstanding at any given time shall be determined by adding (x) the number of shares of Common Stock outstanding as of such
time that are Registrable Securities and (y) the number of shares of Common Stock that are not outstanding as of such time but that are issuable (directly or indirectly) as of such time pursuant to then exercisable and/or convertible securities
and that are Registrable Securities. 
 “Restated Certificate” means the Company’s Amended and Restated Certificate of
Incorporation, as amended and/or restated from time to time. 
 “Restricted Securities” means the securities of the Company
required to bear the legend set forth in Section 2.12(b) hereof. 
 “Requirement of Law” means,
with respect to any Person, any law, treaty, order, statute, ordinance, code, decree, rule, or regulation of a Governmental Authority, in each case legally binding on that Person or to which any of such Person’s assets is legally subject. 

“SEC” means the Securities and Exchange Commission. 

“SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

  
 4 

 “SEC Rule 144(b)(1)(i)” means subsection (b)(1)(i) of SEC Rule 144, as it
applies to persons who have held shares for more than one year. 
 “SEC Rule 145” means Rule 145 promulgated by the SEC
under the Securities Act. 
 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder. 
 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer
taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in
Section 2.6. 
 “Series A Preferred Stock” means shares of the Company’s Series A Preferred
Stock, par value $0.01 per share. 
 “Series B Preferred Stock” means shares of the Company’s Series B Preferred
Stock, par value $0.01 per share. 
 “Series B Purchase Agreement” means that certain Series B Preferred Stock Purchase
Agreement by and among the Company and the investors party thereto, dated as of April 27, 2010. 
 “Series C Preferred
Stock” means shares of the Company’s Series C Preferred Stock, par value $0.01 per share. 
 “Series C Purchase
Agreement” means that certain Series C Preferred Stock Purchase Agreement by and among the Company and the investors party thereto, dated as of December 11, 2012. 

“Series D Preferred Stock” means the shares of the Company’s Series D Preferred Stock, par value $0.01 per share. 

“Series D Purchase Agreement” means that certain Series D Preferred Stock Purchase Agreement by and among the Company and the
Trust, dated as of June 15, 2015. 
 “Series E Preferred Stock” means the shares of the Company’s Series E
Preferred Stock, par value $0.01 per share. 
 “Shaw” means David E. Shaw. 

“Trust” means the Bill & Melinda Gates Foundation Trust. 

“Trust-Controlled Entity” means (a) any entity that is controlled, directly or indirectly, by the Trust or any of its
trustees (such entities including, without limitation, Cascade) and (b) any publicly traded entity in which the Trust or any of its trustees holds, directly or indirectly, five percent (5%) or more of the voting interest in such entity. 

  
 5 

 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after five (5) years after the date of this Agreement
the Company receives a request from Holders of at least thirty-three percent (33%) of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement covering the
registration of Registrable Securities with an anticipated aggregate offering price, net of Selling Expenses, of at least $10,000,000, then the Company shall (i) within ten (10) days after the date such request is received, give notice
thereof (the “S-1 Demand Registration Initiation Notice”) to all Holders other than the Initiating Holders; and (ii) use its best efforts to, as soon as practicable after the date
such request is received from the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered
and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the
S-1 Demand Registration Initiation Notice is given, and in each case, subject to the limitations set forth in Section 2.1(c), Section 2.1(d), and
Section 2.3. 
 (b) Form S-3 Demand. If at any time when it is
eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least ten percent (10%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $1,000,000, then the Company shall
(i) within ten (10) days after the date such request is received, give notice thereof (the “S-3 Demand Registration Initiation Notice”) to all Holders other than the Initiating
Holders; and (ii) use its best efforts to, as soon as practicable, and in any event within sixty (60) days after the date such request is received from the Initiating Holders, file a Form S-3
registration statement under the Securities Act covering all Registrable Securities that the initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders,
as specified by notice given by each such Holder to the Company within twenty (20) days of the date the S-3 Demand Registration Initiation Notice is given, and in each case, subject to the limitations set
forth in Section 2.1(c), Section 2.1(d), and Section 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Section 2.1 a certificate signed by the Company’s chief executive officer or president stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company
and its stockholders for such registration statement either to become effective or to remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially
interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving
as confidential; (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act or (iv) otherwise not be in the best interest of the Company and its stockholders, then the Company shall have the
right to defer taking action with respect to such requested 

  
 6 

 
registration pursuant to this Section 2.1, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more
than ninety (90) days (in the case of a request for registration made pursuant to Section 2.1(a)) or one hundred twenty (120) days (in the case of a request for registration made pursuant to
Section 2.1(b)) after the request of the Initiating Holders is received by the Company; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period with respect
to a request for registration made pursuant to Section 2.1(a) and once in any twelve (12) month period with respect to a request for registration made pursuant to Section 2.1(b). 

(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Section 2.1(a) (i) during any period beginning ninety (90) days before the Company’s good faith estimate of the date of filing of a registration statement for the Company’s IPO or thirty (30) days
before the Company’s good faith estimate of the date of filing of a registration statement for a registration of the Company’s securities other than the Company’s IPO, provided, that the Company is actively employing its best
efforts to cause such registration statement to become effective and the Holders are provided with written notice from the Company regarding such proposed registration within 30 days of the Company’s receiving a given request for registration
pursuant to Section 2.1(a); (ii) during the one hundred eighty (180) day period commencing with the effective date of the Company’s IPO or the ninety (90) day period commencing with the effective date of a
registration of the Company’s securities other than the Company’s IPO; (iii) after the Company has effected two registrations pursuant to Section 2.1(a); or (iv) if the Initiating Holders propose to
dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b). The Company shall not be obligated to
effect, or to take any action to effect, any registration pursuant to Section 2.1(b) (x) during any period beginning thirty (30) days before the Company’s good faith estimate of the date of filing of a
registration statement for a registration of the Company’s securities, provided, that the Company is actively employing its best efforts to cause such registration statement to become effective and the Holders are provided with written
notice from the Company regarding such proposed registration within 30 days of the Company’s receiving a given request for registration pursuant to Section 2.1(b); (y) during the ninety (90) day period commencing
with the effective date of a registration of the Company’s securities; or (z) if the Company has effected a registration pursuant to Section 2.1(b) within the preceding twelve (12) months. A registration
shall not be counted as “effected” for purposes of this Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC; provided, however, that if the
Initiating Holders withdraw their request for a given registration requested pursuant to Section 2.1(a) or Section 2.1(b), elect not to pay the registration expenses therefor, and, pursuant to
Section 2.6, forfeit (I) in the case of a registration proceeding begun pursuant to Section 2.1(a), their right to one registration pursuant to
Section 2.1(a) or (II) in the case of a registration proceeding begun pursuant to Section 2.1(b), their right to request a registration pursuant to
Section 2.1(b) for a period of twelve (12) months, such withdrawn registration statement shall be counted as “effected” for purposes of this Section 2.1(d). 

2.2 Company Registration. If, other than in an Excluded Registration, the Company proposes to register (for the benefit of the Company
and/or for one or more stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash, the Company shall, at such

  
 7 

 
time, promptly give each Holder notice of such proposed registration. Upon the request of any Holder received by the Company within twenty (20) days after such notice is given by the
Company, the Company shall, subject to the provisions of Section 2.3, use its best efforts to cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration.
The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has requested to include
Registrable Securities in such registration. The expenses of any such withdrawn registration shall be borne by the Company in accordance with Section 2.6. 

2.3 Underwriting Requirements. 

(a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by
their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the
S-1 Demand Registration Initiation Notice or the S-3 Demand Registration Initiation Notice, as applicable. The underwriter(s) will be selected by the Company and shall
be reasonably acceptable to a majority in interest of the Initiating Holders. The right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such
underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as
provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 2.3,
if the managing underwriter(s) advise(s) the Company in writing that marketing factors and/or other market conditions require a limitation on the number of shares to be underwritten, then the Company shall so advise the Holders of all Registrable
Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities to be included in the underwriting shall be allocated among such Holders, including the Initiating Holders, in proportion (as nearly as
practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by the Company and all such selling Holders; provided, however, that the number of Registrable Securities to
be included in such underwriting that are held by Holders shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company
or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. 
 (b) In connection with any offering
involving an underwriting of shares of the Company’s capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the
Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the
Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable
discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, 

  
 8 

 
including Registrable Securities, which the underwriters in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of
the Registrable Securities requested to be registered can be included in such offering, then the number of Registrable Securities to be included in such offering shall be allocated among the Holders requesting to participate in such offering in
proportion (as nearly as practicable) to the number of Registrable Securities owned by each selling Holder or in such other proportion as shall mutually be agreed to by the Company and all such selling Holders. To facilitate the allocation of shares
in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities
included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering and (ii) the number of Registrable Securities included in the offering be reduced
below twenty-five percent (25%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the number of Registrable Securities included in the offering may be reduced further (including to zero) if
the underwriters make the determination described above and no other stockholder’s securities are included in such offering. 
 (c) For
purposes of the provisions in Section 2.3(a) and Section 2.3(b) concerning the allocation among Holders of the number of Registrable Securities to be included in an offering, for any selling Holder
that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder and the estates and Immediate Family Members of any such partners, retired
partners, members, and retired members, and any trusts for the benefit of any of the foregoing Persons, shall be deemed, together with such Holder, to be a single “Aggregate Holder,” and any pro rata reduction with respect to such Holder
shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such Aggregate Holder, as defined in this sentence. 

2.4 Obligations of the Company. Whenever required under this Section 2 to effect the registration of any
Registrable Securities, the Company shall use its best efforts to: 
 (a) prepare and file with the SEC a registration statement with
respect to such Registrable Securities and cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a
period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that such one hundred twenty (120) day period shall be extended
for a period of time equal to the period any Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

  
 9 

 (c) furnish to the selling Holders such numbers of copies of a prospectus, including a
preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) register and qualify the securities covered by such registration statement under such other securities or
blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to
service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) cause all such Registrable Securities covered by such registration
statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for
all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available for
inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling
Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

  
 10 

 2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in
connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the
Company; and the reasonable fees and disbursements, not to exceed $30,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be
required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities
proposed to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the
Registrable Securities agree to forfeit (a) in the case of a registration proceeding begun pursuant to Section 2.1(a), their right to one registration pursuant to
Section 2.1(a) or (b) in the case of a registration proceeding begun pursuant to Section 2.1(b), their right to request a registration pursuant to
Section 2.1(b) for a period of twelve (12) months. All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata
on the basis of the number of Registrable Securities registered on their behalf. 
 2.7 Delay of Registration. No Holder shall have
any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2.

 2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling
Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who
controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other
expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the
Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling
Person, or other aforementioned Person expressly for use in connection with such registration. 

  
 11 

 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will
indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any) who controls the Company within the meaning of the Securities Act, legal counsel and accountants
for the Company and/or other aforementioned Person, any underwriter (as defined in the Securities Act) for the Company and/or other aforementioned Person, any other Holder selling securities in such registration statement, and any controlling Person
of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions of, or made in reliance upon and in conformity with written information furnished by
or on behalf of, such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in
connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall
not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the
aggregate amounts payable by any Holder by way of indemnity or contribution under Sections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the
case of fraud or willful misconduct by such Holder. 
 (c) Promptly after receipt by an indemnified party under this
Section 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be
made against any indemnifying party under this Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the
indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified
party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of
such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure
to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent
that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve the indemnifying party of any liability that it may have to any indemnified
party otherwise than under this Section 2.8. 
 (d) To provide for just and equitable contribution to joint liability under the
Securities Act in any case in which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a
final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this
Section 2.8 

  
 12 

 
provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as
is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to
reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material
fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct
or prevent such statement or omission; provided, however, that, in any such case, (x) no Holder will be required to contribute any amount in excess of the public offering price of all Registrable Securities offered and sold by such
Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of
such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to
Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the
termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC
Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the
Company shall: 
 (a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule
144, at all times after the effective date of the registration statement filed by the Company for the IPO; 
 (b) use its best efforts to
file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

  
 13 

 (c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith
upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration
statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to
Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such
other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting
requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of at least seventy percent (70%) of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that (i) would allow such holder or
prospective holder to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such
securities will not reduce the number of the Registrable Securities of the Holders that are included or (ii) would allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or
prospective holder. 
 2.11 “Market Stand off” Agreement. Each Holder hereby agrees that it will not,
without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO, and ending on the date specified by the Company and the managing underwriter (such period not to
exceed one hundred eighty (180) days, provided that such period may be extended upon the request of the managing underwriter, to the extent required to accommodate regulatory restrictions on (1) the publication or other distribution of
research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2241 or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell;
sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible
into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for such IPO or (ii) enter into any swap or other arrangement that transfers to another, in
whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The
foregoing provisions of this Section 2.11 shall apply only to the IPO, and shall not apply to (x) the sale of any shares of Common Stock to an underwriter pursuant to an underwriting agreement, nor (y) any
transaction involving any shares of Common Stock acquired in the IPO or in any after-market transaction. The terms and conditions of this Section 2.11 shall be applicable to any Holder only if all officers, directors and
stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock 

  
 14 

 
(after giving effect to conversion into Common Stock of all outstanding Preferred Stock and all outstanding Non-Voting Common Stock) are subject to
substantially similar restrictions. The underwriters in connection with such registration are intended third-party beneficiaries of this Section 2.11 and shall have the right, power, and authority to enforce the provisions
hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this
Section 2.11 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all
Holders subject to such agreements, based on the number of shares subject to such agreements. 
 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and/or the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 
 (b) Each certificate or instrument representing (i) the Preferred
Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar
event, shall (unless otherwise permitted by the provisions of Section 2.12(c)) be stamped or otherwise imprinted with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and giving instructions
to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

  
 15 

 (c) The holder of each certificate representing Restricted Securities, by acceptance
thereof, agrees to comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the
Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the
proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall,
be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that
the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory
to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to
sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company, subject to the provisions of this Section 2. The Company will not require such a legal
opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144 or (y) in any transaction in which such Holder distributes or transfers Restricted Securities to an Affiliate, subsidiary, parent, partner,
limited partner, retired partner, member, retired member, stockholder, or Immediate Family Member of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Section 2.12. Each
certificate or instrument evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in
Section 2.12(b), except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any
provisions of the Securities Act. 
 2.13 Termination of Registration Rights. The right of any Holder to request registration or
inclusion of Registrable Securities in any registration pursuant to Section 2.1 or Section 2.2 shall terminate upon the earlier to occur of: 

(a) when all of such Holder’s Registrable Securities can be sold in any three (3) month period without registration in compliance
with Rule 144; and 
 (b) the fifth anniversary of the IPO. 

3. Information and Observer Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board of Directors has not
reasonably determined that such Major Investor is directly or indirectly through an Affiliate a competitor of the Company: 
 (a) as soon as
practicable, but in any event within one hundred eighty (180) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and
(iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company; 

  
 16 

 (b) as soon as practicable, but in any event within forty-five (45) days after the end
of each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in
accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with
GAAP); 
 (c) as soon as practicable, but in any event no less than thirty (30) days before the beginning of each fiscal year, an
annual operating plan for such fiscal year and, promptly after prepared, any other budgets or revised budgets prepared by the Company; 
 If, for any
period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to this Section 3.1 shall be the consolidated and
consolidating financial statements of the Company and all such consolidated subsidiaries. 
 For purposes of this Section 3.1,
none of D. E. Shaw Research LLC, D. E. Shaw Technology Development, LLC, Deerfield, WuXi or the Trust shall be deemed a competitor of the Company. 

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this
Section 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply
with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer actively
employing its best efforts to cause such registration statement to become effective. 
 3.2 Inspection. The Company shall permit each
Major Investor (provided that the Board of Directors has not reasonably determined that such Major Investor is directly or indirectly through an Affiliate a competitor of the Company), at such Major Investor’s expense, to visit and inspect the
Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor;
provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information
(unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. For purposes of this
Section 3.2, none of D. E. Shaw Research LLC, D. E. Shaw Technology Development, LLC, or the Trust shall be deemed a competitor of the Company. 

3.3 Observer Rights; Board Materials. 

(a) Trust Observer Rights. As long as the Trust owns not less than twenty-five percent (25%) of the aggregate of (i) the shares of
the Series B Preferred Stock originally sold under the Series B Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion thereof or Non-Voting Common Stock issued in connection with

  
 17 

 
an exchange thereof), (ii) the shares of the Series C Preferred Stock originally sold under the Series C Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion thereof
or Non-Voting Common Stock issued in connection with an exchange thereof), (iii) the shares of the Series D Preferred Stock originally sold to the Trust under the Series D Purchase Agreement (or an equivalent
amount of Common Stock issued upon conversion thereof or Non-Voting Common Stock issued in connection with an exchange thereof) and (iv) the shares of the Series E Preferred Stock originally sold to the
Trust under the Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion thereof or Non-Voting Common Stock issued in connection with an exchange thereof), the Company shall invite a
representative of the Trust to attend all meetings of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its
directors; provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided and, if requested by the Company, enter into a confidentiality agreement
with the Company in form prescribed by the Company; and provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if (a) access to such information
or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or create a conflict of interest, or (b) result in disclosure of trade secrets to a competitor of the Company. 

(b) WuXi Board Materials. As along as WuXi, together with its Affiliates, owns not less than all of the shares of Series E Preferred
Stock originally sold to WuXi under the Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion thereof, and as adjusted for any stock split, stock dividend, combination or other recapitalization or reclassification
effected after the date hereof), the Company shall provide WuXi copies of all notices, minutes, consents, and other materials that it provides to its Board of Directors; provided, however, that WuXi shall agree to hold in confidence and trust and to
act in a fiduciary manner with respect to all information so provided and, if requested by the Company, enter into a confidentiality agreement with the Company in form prescribed by the Company; and provided further, that the Company reserves the
right to withhold any information if access to such information could (a) adversely affect the attorney client privilege between the Company and its counsel or create a conflict of interest, or (b) result in disclosure of trade secrets to
a competitor of the Company. 
 3.4 Termination of Information and Observer Rights. The covenants set forth in
Section 3.1, Section 3.2, and Section 3.3 shall terminate and be of no further force or effect upon the consummation of a Qualified IPO (as such term is defined in the
Restated Certificate). 
 3.5 Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose,
divulge, or use for any purpose (other than in connection with its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a
registration statement), unless such confidential information (a) is known or becomes known to the public (other than as a result of a breach of this Section 3.5 by such Investor), (b) is or has been independently
developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third 

  
 18 

 
party without a breach of any obligation of confidentiality known by the Investor to be owing by such third party to the Company; provided, however, that an Investor may disclose confidential
information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of
any Registrable Securities or Preferred Stock from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 3.5; (iii) to any existing or prospective Affiliate, partner, member,
stockholder, wholly owned subsidiary, or financing sources of such Investor, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information (and, in
the case of a prospective Affiliate, partner, member, stockholder, wholly owned subsidiary, or financing source, is bound by a confidentiality agreement no less restrictive than this Section 3.5 with respect to such information); or
(iv) (A) as may otherwise be required by law or under the terms of a subpoena, order, or other document issued by a court, governmental body, or stock exchange, in each case based on the opinion of such Investor’s counsel, or (B) in
connection with any judicial or administrative proceeding (including in response to questions, interrogatories, and/or requests for information and/or documents) in which such Investor is involved, provided, in each case (A) and (B), that the
Investor promptly notifies the Company of such disclosure. The Company acknowledges that (i) Deerfield and its Affiliates (which include, for purposes hereof, any professional investment funds managed by Deerfield or any of its Affiliates) are
engaged in the business of public market and private equity investing and may from time to time invest in entities that develop and utilize technologies, products or services that are similar to or competitive with those of the Company, and
(ii) except insofar as this Agreement restricts the disclosure of the confidential information, this Agreement shall not prevent Deerfield or its Affiliates from (a) engaging in or operating any business, (b) entering into any
agreement or business relationship with any third party, or (c) evaluating or engaging in investment discussions with, or investing in, any third party, whether or not competitive with the Company or its Affiliates. The Company acknowledges
that Deerfield’s review of confidential information will inevitably enhance its knowledge and understanding of the business of the Company in a way that cannot be separated from Deerfield’s other knowledge and Company agrees that this
Agreement shall not restrict Deerfield in connection with the purchase, sale, consideration of, and decisions related to other investments and serving on the boards of such investments in such industries. The Company acknowledges that Deerfield or
its Affiliates’ directors, officers or employees may serve as directors of portfolio companies of investment funds managed by Deerfield, and the Company agrees that such portfolio companies will not be deemed to have received confidential
information solely because any such individual serves on the board of such portfolio company, provided that (i) such individual or Deerfield or any Affiliate has not provided such portfolio company or any other director, officer, employee or
other representative of such portfolio company with confidential information and (ii) such portfolio company does not act at the direction of or with encouragement from Deerfield. Furthermore, nothing in this Agreement will be construed as a
representation or agreement that Deerfield or its Affiliates will not develop, receive or otherwise possess ideas, plans or other information which may be similar to that embodied in the confidential information, provided that such ideas, plans or
other information has not been prepared in reliance upon or otherwise using the confidential information or otherwise in violation of this Section 3.5. The Company further acknowledges that Deerfield does not want to receive any material non-public information with respect to any publicly-traded company, and the Company agrees that it will use reasonable efforts not to disclose any such information to Deerfield. 

  
 19 

 4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities
laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to (i) each Investor holding shares of Series A Preferred Stock and (ii) each Major Investor (provided that the Board of
Directors has not reasonably determined that such Major Investor is directly or indirectly through an Affiliate a competitor of the Company). An Investor shall be entitled to apportion the right of first offer hereby granted to it among itself and
its Affiliates in such proportions as it deems appropriate. As used in this Section 4, the term “Investor” shall refer only to the Investors described in clauses (i) and (ii) of the first sentence of this Section 4.1. 

(a) The Company shall give notice (the “New Securities Offer Notice”) to each Investor, stating (i) its bona fide
intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the New Securities Offer Notice is given, each Investor may elect to
purchase or otherwise acquire, at the price and on the terms specified in the New Securities Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock issued and held, or issuable (directly or
indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock, Non-Voting Common Stock and any other Derivative Securities then held, by such Investor bears to the total Common Stock of
the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock, Non-Voting Common Stock and other Derivative Securities). At the expiration of such twenty
(20) day period, the Company shall promptly notify each Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Investor’s failure to do likewise,
including in such notice the total number of shares that Investors other than the Fully Exercising Investors failed to elect to purchase (the “Remaining New Securities”). During the ten (10) day period commencing when the
Company has given such notice to the Fully Exercising Investors, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the
Remaining New Securities which equals the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock, Non-Voting
Common Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock, Non-Voting Common Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase any such Remaining New Securities. The closing of any sale pursuant to this
Section 4.1(b) shall occur within the later of one hundred and twenty (120) days of the date that the New Securities Offer Notice is given and the date of initial sale of New Securities pursuant to
Section 4.1(c). 

  
 20 

 (c) The Company may, during the one hundred and twenty (120) day period following the
expiration of the periods provided in Section 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the
offeree than, those specified in the New Securities Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within sixty (60) days of the
execution thereof, the Investors’ right of first offer provided in this Section 4.1 shall be deemed to be revived and such New Securities shall not be offered or sold to any Person or Persons other than the Investors
unless first reoffered to the Investors in accordance with this Section 4.1. 
 (d) The right of first offer in
this Section 4.1 shall not be applicable to Exempted Securities (as defined in the Restated Certificate). 
 4.2
Termination. The covenants set forth in Section 4.1 shall terminate and be of no further force or effect (i) immediately before the consummation of a Qualified IPO or (ii) upon a Deemed Liquidation Event,
as such term is defined in the Restated Certificate, whichever event occurs first. 
 5. Additional Covenants. For the purposes of
this Section 5, the term “the Company” shall include Schrödinger, LLC (the “LLC”) unless otherwise noted herein. 

5.1 Employee Agreements. The Company will cause (i) each person now or hereafter employed by it or by any subsidiary (or engaged by
the Company or by any subsidiary as a consultant or independent contractor) to enter into a nondisclosure and proprietary rights assignment agreement, which in the case of employees shall be in the form provided to the Trust or its counsel and
(ii) each Key Employee to enter into a standard employment agreement, including, to the extent permitted by applicable law without the need for the Company to pay such employee additional consideration in excess of $10,000, noncompetition and
nonsolicitation provisions substantially in the form attached hereto as Exhibit A. 
 5.2 Employee Stock. Unless otherwise
approved by the Board of Directors, all employees, consultants, directors and other service providers of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof
shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with twenty-five percent (25%) of such shares vesting on each anniversary of the vesting
commencement date for such option or shares, provided that such employee, consultant, director or other service provider has provided continued employment or service to the Company during such period, and (ii) a market stand-off provision substantially similar to that in Section 2.11. In addition, unless otherwise approved by the Board of Directors, with respect to all equity grants other than those made
pursuant to the Company’s 2002 Amended and Restated Stock Incentive Plan, the Company (A) shall retain (and not waive) a “right of first refusal” on employee, consultant, director and other service provider transfers of the
Company’s capital stock until the Company’s IPO, (B) shall have the right to repurchase, at cost, unvested shares, if any, held by such employee, consultant, director or other service provider upon termination of employment or
service, as applicable, of a recipient of a grant of restricted stock, and (C) shall have the right to repurchase, at cost, vested shares, if any, held by such employee, consultant, director or other service provider upon termination of
employment or service, as applicable, for “Cause” (as defined in the applicable restricted stock agreement) of a recipient of a grant of restricted stock. 

  
 21 

 5.3 Matters Requiring Investor Director Approval. So long as the holders of Series B
Preferred Stock, Series C Preferred Stock and Series D Preferred Stock are entitled to elect a Series B/C/D Director (as defined in the Restated Certificate), the Company hereby covenants and agrees with each of the Investors that it shall not,
without approval of the Board of Directors, which approval must include the affirmative vote of the then-serving Series B/C/D Director: 

(a) (i) enter into any joint venture or (ii) enter into any agreement in connection with sponsored research, collaboration, technology
license, development, OEM, marketing or other similar agreements or strategic partnerships in which the aggregate value to or obligation of the Company is greater than $10,000,000, provided that the approval otherwise required pursuant to this
Section 5.3 shall not be required with respect to any such joint venture, agreement, strategic partnership or other arrangement described in this Section 5.3(a) if (x) Deerfield Management Company, L.P. (“Deerfield”), any
Affiliate of Deerfield or any entity in which either Deerfield or any of Affiliate of Deerfield (collectively, the “Deerfield-Related Entities”), directly or indirectly, holds a voting interest in, or is issued or holds stock of, a
principal party to such transaction (other than the Company) that represents beneficial ownership of not less than 5% of the equity of such principal party, (y) such Deerfield-Related Entity either (A) controls (as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended) a principal party to such transaction (other than the Company), or (B) is a “major investor,” “major holder” or has comparable
status with respect to a principal party to such transaction (other than the Company) as and to the extent that the term “major investor,” “major holder” or any comparable term that conveys participation, information and co-sale rights, is understood or defined with respect to such party’s governing corporate documents and (z) such transaction has been approved by the Board of Directors; 

(b) authorize the acquisition of any other entity or business, which shall include, without limitation, financial investments of at least
$5,000,000 in cash; or 
 (c) make any capital expenditures in a single transaction or series of related transactions in excess of
$7,500,000. 
 5.4 Affirmative Obligations of the Company. 

(a) At all times after the execution and delivery of the Agreement, the Company shall: 

(i) acquire and maintain sufficient legal rights to use and to exploit, in the conduct of the Company’s business, all Intellectual
Property (as defined in the Purchase Agreement) that is necessary to the conduct of the Company’s business or that otherwise is used or exploited in such business; 

(ii) promptly following general commercial release of new versions, register with the United States Copyright Office the Company’s
material existing and newly developed original works of authorship to the extent such works are eligible for registration with the United States Copyright Office and not already so registered; 

  
 22 

 (iii) require each employee hired by the Company or by any subsidiary following the
execution and delivery of this Agreement to execute and deliver to the Company a form of written employment agreement, which will provide that such employee will be required to assign to the Company all Intellectual Property he or she makes,
creates, conceives or first reduces to practice in the course of his or her employment, whether or not such Intellectual Property is made, created, conceived or first reduced to practice by such employee alone or with others and whether made,
created, conceived, or first reduced to practice during regular working hours or other hours, and all Intellectual Property he or she makes, creates, conceives or first reduces to practice during the period of his or her employment, whether or not
in the course of such employment, to the extent the same is related to the Company’s business or actual or demonstrably anticipated research or development or is made, created, conceived, or first reduced to practice with the time, private or
proprietary information, or facilities of the Company; provided, however, this clause shall not apply to the employees of Schrödinger, GmbH except for those employees of Schrödinger, GmbH, if any, who are responsible for product
development or quality assurance testing; and 
 (iv) continue the Company’s practice of requiring each consultant involved in any
material way in the conduct of the Company’s business to assign to the Company all Intellectual Property he or she develops or creates that results from the work performed by such consultant for the Company. 

5.5 Negative Obligations. 

(a) At all times after the execution and delivery of the Agreement, the Company shall not, and shall not permit its subsidiaries to, market or
sell any product or service or engage in any other activity which, to the Company’s Knowledge, will violate any license or privacy or publicity rights (or the like), or infringe or misappropriate any Intellectual Property of any other party.

 (b) None of the parties to this Agreement (except the Trust) shall use the Trust’s name (or the name of any Affiliate of the Trust)
in any press release, published notice or other publication relating to the Trust’s investment in the Company without the prior written consent of the Trust, except as may be required to meet the obligations of Section 5.6. For the
avoidance of doubt, the Company may, subject to a confidentiality agreement, advise other investors and prospective investors of the fact of the Trust’s investment in the Company, including the transfer of Cascade’s prior investment in the
Company to the Trust (the “Transfer”), and may make any other disclosure regarding the Trust’s investment in the Company, including the Transfer, required by law or legal process, provided that the Company provides the Trust
reasonable advance notice of such disclosure and the Company may, without a confidentiality agreement, make disclosures regarding the Trust’s investment in the Company, including the Transfer, to the extent such information in such disclosures
is readily publicly available without restriction (except through violation of this Agreement), whether through any previously approved press release or other proper disclosure in compliance with this Agreement, without obtaining the Trust’s
consent or providing advance notice of such disclosures. 

  
 23 

 5.6 Cooperation with the Trust. Prior to entering into a commercial agreement with
any third party that will involve the payment of any consideration to or for the benefit of such third party in excess of US$100,000.00 in a single transaction (or a series of related transactions) (each such third party, an “Applicable
Vendor”, and each such potential commercial agreement, an “Applicable Vendor Agreement”), the Company will notify the Trust of the name and address of such Applicable Vendor (such notice, the “Company Notice”).
The Trust will then make a determination as to whether William H. Gates, III (“Gates”) holds, directly or indirectly, an ownership interest in such Applicable Vendor (each such ownership interest a “Qualified
Interest”). The Trust shall notify the Company within ten (10) business days following the date of the Company Notice whether or not Gates holds a Qualified Interest (the “Trust Notice”). If the Trust Notice indicates
that Gates holds a Qualified Interest, then the Company shall cooperate with the Trust in structuring such Applicable Vendor Agreement in a manner that will not give rise to potential adverse consequences to the Trust, Gates or the Company. 

5.7 Termination of Covenants. The covenants set forth in this Section 5, shall terminate and be of no further
force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed
Liquidation Event, as such term is defined in the Restated Certificate, whichever event occurs first. Notwithstanding the foregoing, the covenant set forth in Section 5.6 shall terminate and be of no further force or effect
upon the occurrence of any event set forth in clauses (i), (ii) or (iii) of the preceding sentence or (iv) upon the Trust no longer holding any equity securities of the Company, whichever event occurs first. 

6. Miscellaneous. 
 6.1
Successors and Assigns. 
 (a) The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to
a transferee of Registrable Securities that (i) is an Affiliate, subsidiary, parent, partner, limited partner, retired partner, member, retired member, or a stockholder of a Holder; (ii) is a Holder’s Immediate Family Member or a
trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; (iii) after such transfer, holds at least 3,000,000 shares of Registrable Securities (subject to appropriate adjustment for stock
splits, stock dividends, combinations, and other recapitalizations); or (iv) any charitable organization formed by a Holder, or by any of the entities listed in clauses (i)-(iii) above, provided, however, that (x) the Company is, within a
reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written
instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11. Notwithstanding the foregoing or anything to the contrary in this
Agreement, Scott Becker may only transfer his rights under this Agreement to an Immediate Family Member or a trust for his benefit or the benefit of an Immediate Family Member. 

  
 24 

 (b) For the purposes of determining the number of shares of Registrable Securities held by
a transferee, the holdings of a transferee (i) that is an Affiliate or stockholder of a Holder; (ii) who is a Holder’s Immediate Family Member; or (iii) that is a trust for the benefit of an individual Holder or such
Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. 

(c) The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and assignees of the
parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of
this Agreement, except as expressly provided herein. 
 (d) Notwithstanding anything to the contrary in this Agreement, in the event that
Shaw sells or transfers more than twenty-five percent (25%) of the shares of Series A Preferred Stock held by Shaw on the date of this Agreement to any corporation, partnership, association, limited liability company, joint venture, trust,
unincorporated organization or organization similar to the foregoing that the Trust reasonably and in good faith determines is a competitor to any Trust-Controlled Entity, then the Trust shall have the right to sell or transfer all or any portion of
the shares of Preferred Stock then held by the Trust and the provisions of Section 6.1(a) of this Agreement shall be inapplicable to such sale or transfer. 

6.2 Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless
of the laws that might otherwise govern under applicable principles of conflicts of law. 
 6.3 Counterparts; Facsimile. This
Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed and delivered by facsimile signature and in
two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of: (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business
hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1)
business day after the 

  
 25 

 
business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of
receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or
to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Section 6.5. If notice is given to the Company, a copy of such notice (which shall not constitute
notice under this Agreement) shall also be sent to Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, MA 02109, Attention: Cynthia T. Mazareas, Esq. 

6.6 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of at least seventy percent (70%) of the Registrable Securities then outstanding; provided that
the Company may in its sole discretion waive compliance with Section 2.12(c); provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other
party; provided, further, that (A) romanette (ii) in the definition of “Major Investor” set forth in Section 1 of this Agreement and this proviso (A) may not be amended or waived without the consent of Deerfield;
(B) romanette (iii) in the definition of “Major Investor” set forth in Section 1 of this Agreement, Section 3.3(b) of this Agreement and this proviso (B) may not be amended or waived without the consent of WuXi;
(C) romanette (iv) in the definition of “Major Investor” set forth in Section 1 of this Agreement and this proviso (C) may not be amended or waived without the consent of Qiming; and (D) romanette (v) in the definition
of “Major Investor” set forth in Section 1 of this Agreement and this proviso (D) may not be amended or waived without the consent of Baron. Notwithstanding the foregoing, (a) this Agreement may not be amended or terminated
and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a
waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain
Investors may nonetheless, by agreement with the Company, purchase securities in such transaction) and (b) Subsections 3.1 and 3.2, Section 4 and any other section of this Agreement applicable to the
Major Investors (including this clause (b) of this Subsection 6.6) may not be amended, modified, terminated or waived without the written consent of the holders of at least a majority of the Registrable Securities then outstanding held
by the Major Investors. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or
waiver effected in accordance with this Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of
this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid,
legal, and enforceable to the maximum extent permitted by law. 

  
 26 

 6.8 Aggregation of Stock. All shares of Registrable Securities held or acquired by
Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement, including whether an Investor is a “Major Investor”, and such persons may apportion such rights as among themselves
in any manner they deem appropriate. 
 6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the
Company issues additional shares of the Company’s Series E Preferred Stock after the date hereof pursuant to the Purchase Agreement, as amended and/or restated from time to time, any purchaser of such shares of Series E Preferred Stock may
become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall
be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations of an “Investor” hereunder. 

6.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and
agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement, the
Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement and shall be of no further force or effect. 

6.11 Limited Permission for a Party to Seek Specific Performance. 

(a) A Holder shall have the right to seek the remedy of specific performance in a Covered Dispute (as defined in
Section 6.12 below) against another Holder (“Other Holder”) in order to prevent a breach or a continuing breach, as applicable, by such Other Holder of express provisions of a covenant set forth in this
Agreement (or exhibits thereto), subject to all of the limitations set forth in this Section 6.11 and Section 6.12 below. 

(b) For the avoidance of doubt, (i) the Company shall not have the right to seek the remedy of specific performance in a Covered Dispute
against any Holder (provided that, and not withstanding anything herein to the contrary, the Company shall retain any and all rights with respect to specific performance and/or other remedies pursuant to the Employment Agreement between it and Scott
Becker dated as of January 11, 2012); (ii) nothing in this Section 6.11 implies a waiver of any defense to the remedy of specific performance, including the defense that a remedy of monetary damages would be adequate;
(iii) any right provided to a party in Section 6.11(a) to seek specific performance shall be deemed to be subject to all limitations in this Agreement applicable to such right (including the limitations set forth in
Section 6.12); and (iv) each party agrees that it shall not seek any remedy of specific performance, other than as expressly set forth in this Section 6.11. 

  
 27 

 (c) Notwithstanding anything to the contrary in this Agreement, no specific performance
remedy may be granted against another party if it would require such party to breach or violate any Requirement of Law. 
 6.12 Dispute
Resolution. 
 (a) Any and all disputes, claims, or controversies arising out of or relating to this Agreement, or the breach thereof,
will be resolved in accordance with the procedures set forth in this Section 6.12 (each, a “Covered Dispute”), and these procedures will be the sole and exclusive process for the resolution of such Covered
Disputes. Notwithstanding anything to the contrary in this Agreement and solely with respect to claims of a Holder against the Company that may arise out of or relating to this Agreement or the breach thereof, the Company (i) hereby irrevocably
and unconditionally submits to the jurisdiction of the federal and state courts located within the geographic boundaries of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising
out of or based upon this Agreement, (ii) agrees not to commence any suit, action or other proceeding arising out of or based upon this Agreement against any Holder and/or its Affiliates or Cascade and/or its Affiliates, and (iii) hereby
waives, and agrees not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune
from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such
court. 
 (b) Any Covered Dispute will be finally settled by arbitration administered by the American Arbitration Association in accordance
with its Commercial Arbitration Rules then in effect, except as modified herein. 
 (c) The number of arbitrators will be three, one of whom
will be appointed by each of the parties to the Covered Dispute, and the third of whom will be selected by mutual agreement of the parties to the Covered Dispute, if possible, within ten (10) business days after the selection of the second
arbitrator and thereafter by the administering authority; provided, that in the event a given Covered Dispute shall have more than two disputing parties (counting as a single party for purposes of this sentence any parties whose interests are
substantially identical), such Covered Dispute shall be separated into multiple separate Covered Disputes, each of which shall have only two parties. The place of arbitration will be New York, New York. The arbitrators shall be chosen from the
American Arbitration Association’s “National Panel” and shall have extensive commercial experience that the parties to the Covered Dispute believe in good faith is sufficient given the nature and complexity of this Agreement. 

(d) The arbitrators will have no authority (i) to make any ruling, finding, or award that does not conform to the terms and conditions of
this Agreement or (ii) to grant a remedy of specific performance other than as may be sought pursuant to and in accordance with this Section 6.12. 

  
 28 

 (e) The award of the arbitrators will be final and binding. Judgment on the award rendered
by the arbitrators may be entered in any court having jurisdiction thereof, provided that any award of specific performance shall (i) be documented in a detailed written opinion containing findings of fact and law, subject to
Section 6.12(h) below, and (ii) be subject to review by any court to which such award is submitted for entry to the same extent that a similar award by the New York Supreme Court would be subject to review by the
Appellate Division of the New York Supreme Court. 
 (f) Notwithstanding anything to the contrary in this
Section 6.12, any party may apply to a court of competent jurisdiction solely (i) to seek injunctive relief in order to maintain the status quo until such time as an arbitration award is rendered or the controversy is
otherwise resolved and/or (ii) to enforce an arbitration award, and for no other purpose. 
 (g) The arbitral tribunal and the
administrator shall agree to keep confidential and not disclose information concerning (i) the existence of an arbitration, (ii) any documentary or other evidence given by a party or witness in the arbitration, or (iii) the
arbitration award, provided that a party may make such disclosures as are necessary to comply with any Requirement of Law or the request of any Governmental Authority after making good faith efforts under the circumstances to consult in
advance with the other Parties. 
 (h) The right of the Holders to seek specific performance granted by
Section 6.11 is subject to the following limitations: 
 (i) a Holder that intends to bring an action to seek
specific performance (the “Seeker”) against another Holder or against Cascade and/or its Affiliates (the “Alleged Breaching Party”) shall give the Alleged Breaching Party notice of its intention to bring such action
as promptly as reasonably practicable after the Seeker learns of the acts or omissions giving rise to the alleged breach; 
 (ii) the Seeker
shall not seek an order the compliance with which is beyond the ability or outside the control of the Alleged Breaching Party; 
 (iii) the
Seeker shall not be entitled to any relief or findings of fact made in connection with any remedy that could reasonably be expected to (A) require a Person to violate any applicable law, rule, or regulation; (B) result in a statutory
disqualification of the Alleged Breaching Party or any of its Affiliates and, in the case where the Trust is the Alleged Breaching Party, any other Gates-Related Entity (as defined in Section 6.16(b) below), or result in similar disabilities
imposed upon the Alleged Breaching Party or its Affiliates and, in the case where the Trust is the Alleged Breaching Party, any other Gates-Related Entity, under state or federal securities laws, ERISA, or similar statutes; or (C) result in the
bankruptcy or insolvency of the Alleged Breaching Party; 
 (iv) to the fullest extent permitted by law, the Seeker waives any right to, and
if practicable will oppose, (A) the penalty of incarceration and/or (B) the imposition of penalties for criminal or civil contempt, in each case (A) and (B), for any actual or alleged noncompliance with any order; and 

(v) nothing in this Section 6.12(h) implies a waiver of any defense to the remedy of specific performance, including
the defense that a remedy of monetary damages would be adequate. 

  
 29 

 6.13 Delays or Omissions. No delay or omission to exercise any right, power, or
remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of the party to whom such right, power or remedy accrues, nor shall any such delay
or omission be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or
default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.14 Acknowledgment. The Company acknowledges with respect to each Investor other than Scott Becker that such Investors may be in the
business of (i) venture capital investing and/or other forms of investing in private and/or public companies, (ii) conducting scientific and/or technology-related research and development and/or (iii) developing, marketing, licensing
and/or selling computer software, computer hardware and/or other technology products and/or pharmaceutical products and therefore may independently develop and/or review business plans and proprietary information of many enterprises, including
enterprises that may have products or services that compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict any Investor other than Scott Becker from investing in and/or founding,
developing, operating or otherwise participating in any other way in the business of any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. For the avoidance of doubt, nothing
contained in this paragraph shall be deemed to relieve any Investor of such Investor’s obligations to comply with the terms and conditions of this Agreement, including Section 3.5 hereof, or, in the case of Scott
Becker with the terms of any agreements concerning his employment with the Company. 
 6.15 No Implied Limitation. As used in this
Agreement, the words “include” and “including,” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed in each instance by the words “without limitation.” 

6.16 No Obligation to Cause Actions of Other Entities. 

(a) Each of the Company and each Investor acknowledges and agrees that (a) David E. Shaw has no obligation to cause any Affiliate, any
DESCO Group Entity, D. E. Shaw & Co., L.P., or D. E. Shaw Valence Portfolios, L.L.C. (collectively, the “Other Shaw-Related Entities”) to take any action, or omit to take any action, under and/or in connection with this
Agreement, (b) no personal liability whatsoever (of any type or nature) will attach to, or be incurred by, David E. Shaw because of any incurring by any Other Shaw-Related Entity of any obligation set forth in this Agreement, and (c) any
personal liability of David E. Shaw in respect of any such obligations of any type or nature, and any and all claims for any such liability against David E. Shaw, whether arising in common law or equity or created by rule of law, statute,
constitution, or otherwise, are expressly released and waived by each of the Company and each Investor as a condition of, and as part of the consideration for, the execution and delivery of this Agreement by David E. Shaw. 

  
 30 

 (b) Each of the Company and each Investor acknowledges and agrees that (a) Gates has
no obligation to cause any of the Trust, Cascade, the Bill & Melinda Gates Foundation or any other Affiliate (each, a “Gates-Related Entity”) to take any action, or omit to take any action, under and/or in connection with
this Agreement, (b) no personal liability whatsoever (of any type or nature) will attach to, or be incurred by, Gates because of any incurring by any Gates-Related Entity of any obligation set forth in this Agreement, and (c) any personal
liability of Gates in respect of any such obligations of any type or nature, and any and all claims for any such liability against Gates, whether arising in common law or equity or created by rule of law, statute, constitution, or otherwise, are
expressly released and waived by each of the Company and each Investor as a condition of, and as part of the consideration for, the execution and delivery of this Agreement by the Trust. Each of the Company and each Investor further agrees that
Gates is an intended third-party beneficiary of this Section 6.16(b). 
 (c) Each of the Company and each Investor
acknowledges and agrees that Deerfield has no obligation to cause any Affiliate of Deerfield (collectively, the “Deerfield-Related Entities”) to take any action, or omit to take any action, under and/or in connection with this
Agreement. 
 (d) Each of the Company and each Investor acknowledges and agrees that WuXi has no obligation to cause any Affiliate of WuXi
(collectively, the “WuXi-Related Entities”) to take any action, or omit to take any action, under and/or in connection with this Agreement. 

[Remainder of page intentionally left blank] 

  
 31 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	SCHRÖDINGER, INC.
		
	By:	 	 /s/ Ramy Farid

	Name:	 	Ramy Farid
	Title:	 	President and Chief Executive Officer

 Signature Page to Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	BILL & MELINDA GATES FOUNDATION TRUST
		
	By:	 	 /s/ Alan Heuberger

	Name:	 	Alan Heuberger
	Title:	 	Authorized Representative

 Signature Page to Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	 /s/ David E. Shaw

	David E. Shaw

 Signature Page to Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

	
	INVESTORS:
	
	 /s/ Scott Becker

	Scott Becker

 Signature Page to Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	WUXI PHARMATECH HEALTHCARE FUND I L.P.
		
	By:	 	 /s/ Edward Hu

	Name:	 	Edward Hu
	Title:	 	Authorized Representative

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	BARON GROWTH FUND
		
	By:	 	 /s/ Patrick M. Patalino

	Name:	 	Patrick M. Patalino
	Title:	 	General Counsel

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Deerfield Private Design Fund IV, L.P.
	By: Deerfield Mgmt IV, L.P., its General Partner
	By: J. E. Flynn Capital IV, L.P., its General Partner
		
	By:	 	 /s/ David J. Clark

	Name:	 	David J. Clark
	Title:	 	Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

					
	INVESTORS:
	
	 QIMING VENTURE PARTNERS VI, L.P.,
 a
Cayman Islands exempted limited partnership

		
	    By:	 	QIMING GP VI, L.P. a Cayman Islands exempted limited partnership
		
	    Its:	 	General Partner
			
		 	By:	 	QIMING CORPORATE GP VI, LTD. a Cayman Islands exempted company
			
		 	Its:	 	General Partner
			
		 	By:	 	 /s/ Ryan Baker

		 	Its:	 	Authorized Signatory
	
	QIMING MANAGING DIRECTORS FUND VI, L.P., a Cayman Islands exempted limited partnership
		
	    By:	 	QIMING CORPORATE GP VI, LTD., a Cayman Islands exempted company
		
	    Its:	 	General Partner
			
		 	By:	 	 /s/ Ryan Baker

		 	Its:	 	Authorized Signatory
		
		 	Signing Location: Bellevue, WA USA        
		
		 	Signature of Witness: /s/ Jill Calvo            
		
		 	Name of Witness: Jill Calvo                        

 SCHRÖDINGER, INC. 

Counterpart Signature Page 

to 
 Series E Preferred Stock
Financing Documents 
 By executing and delivering this signature page, the undersigned hereby joins in, becomes a party to and agrees
to be bound by the terms and conditions of: 
  

	(i)	 that certain Series E Preferred Stock Purchase Agreement, dated as of November 9, 2018, by and among
Schrödinger, Inc., a Delaware corporation (the “Company”), and the Purchasers named therein, as amended from time to time (the “Purchase Agreement”), as a “Purchaser” thereunder and acknowledges
having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers,” and hereby represents that the statements contained therein are complete and accurate with respect to the
undersigned as a Purchaser; 

  

	(ii)	 that certain Amended and Restated Voting Agreement, dated as of November 9, 2018, by and among the Company
and the Stockholders (as defined therein), as amended from time to time (the “Voting Agreement”), as an “Investor” and a “Stockholder” thereunder; 

 

	(iii)	 that certain Amended and Restated Investors’ Rights Agreement, dated as of November 9, 2018, by and
among the Company and the Investors (as defined therein), as amended by Amendment No. 1, dated as of the date hereof, and as further amended from time to time (the “Rights Agreement”), as an “Investor” thereunder; and

  

	(iv)	 that certain Amended and Restated Right of First Refusal and Co-Sale
Agreement, dated as of November 9, 2018, by and among the Company, the Investors (as defined therein) and the Key Holders (as defined therein), as amended from time to time (the “Co-Sale
Agreement”), as an “Investor” thereunder. 

 The undersigned hereby authorizes this signature page to
be attached to the Purchase Agreement, the Voting Agreement, the Rights Agreement and the Co-Sale Agreement or counterparts thereof. The undersigned has carefully read each of the agreements listed above,
including without limitation the representations and warranties of the Purchasers in Section 3 of the Purchase Agreement. 
  

							
	INVESTOR:	 	    	 	Number of Shares
3,354,353                                
			
	GV 2019, L.P.	 		 	
	By: GV 2019 GP, L.P., its General Partner	 		 	Aggregate Purchase Price: $4,999,998.59            
	By: GV 2019 GP, L.L.C., its General Partner	 		 	

  

							
	By:	 	 /s/ Daphne M. Chang
	 		 	

							
	Name:   Daphne M. Chang	 		 	
	Address: Authorized Signatory	 		 	
			
	AGREED TO AND ACCEPTED:	 		 	
			
	SCHRÖDINGER, INC.	 		 	

							
				
	By:	 	 /s/ Ramy Farid
	 		 	

							
	Name: Ramy Farid	 		 	
	Title:   President and Chief Executive Officer	 		 	

							
				
	Date:	 	January 4, 2019	 		 	

 SCHRÖDINGER, INC. 

Counterpart Signature Page 

to 
 Series E Preferred Stock
Financing Documents 
 By executing and delivering this signature page, the undersigned hereby joins in, becomes a party to and agrees
to be bound by the terms and conditions of: 
  

	(i)	 that certain Series E Preferred Stock Purchase Agreement, dated as of November 9, 2018, by and among
Schrödinger, Inc., a Delaware corporation (the “Company”), and the Purchasers named therein, as amended from time to time (the “Purchase Agreement”), as a “Purchaser” thereunder and acknowledges
having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers,” and hereby represents that the statements contained therein are complete and accurate with respect to the
undersigned as a Purchaser; 

  

	(ii)	 that certain Amended and Restated Voting Agreement, dated as of November 9, 2018, by and among the Company
and the Stockholders (as defined therein), as amended from time to time (the “Voting Agreement”), as an “Investor” and a “Stockholder” thereunder; 

 

	(iii)	 that certain Amended and Restated Investors’ Rights Agreement, dated as of November 9, 2018, by and
among the Company and the Investors (as defined therein), as amended by Amendment No. 1, dated January 4, 2019 and Amendment No. 2, dated as of the date hereof, and as further amended from time to time (the “Rights
Agreement”), as an “Investor” thereunder; and 

  

	(iv)	 that certain Amended and Restated Right of First Refusal and Co-Sale
Agreement, dated as of November 9, 2018, by and among the Company, the Investors (as defined therein) and the Key Holders (as defined therein), as amended by Amendment No. 1, dated as of the date hereof, and as further amended from time to
time (the “Co-Sale Agreement”), as an “Investor” thereunder. 

The undersigned hereby authorizes this signature page to be attached to the Purchase Agreement, the Voting Agreement, the Rights Agreement and
the Co-Sale Agreement or counterparts thereof. The undersigned has carefully read each of the agreements listed above, including without limitation the representations and warranties of the Purchasers in
Section 3 of the Purchase Agreement. 
  

					
	INVESTOR:	  	            	  	Number of Shares 3,354,353                             
			
	PAV INVESTMENTS PTE. LTD.	  		  	Aggregate Purchase Price: $4,999,998.59        

 

					
	By:	 	 /s/ Lee Yann Fang

					
	Name:	 	LEE YANN FANG        
	Address:	 	[**]
	
	 AGREED TO AND ACCEPTED:
  

SCHRÖDINGER, INC.

					
		
	By:	 	 /s/ Ramy Farid

					
	Name:	 	Ramy Farid
	Title:	 	President and Chief Executive Officer

 Date: April 8, 2019 

 SCHRÖDINGER, INC. 

Counterpart Signature Page 

to 
 Series E Preferred Stock
Financing Documents 
 By executing and delivering this signature page, the undersigned hereby joins in, becomes a party to and agrees
to be bound by the terms and conditions of: 
  

	(i)	 that certain Series E Preferred Stock Purchase Agreement, dated as of November 9, 2018, by and among
Schrödinger, Inc., a Delaware corporation (the “Company”), and the Purchasers named therein, as amended from time to time (the “Purchase Agreement”), as a “Purchaser” thereunder and acknowledges
having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers,” and hereby represents that the statements contained therein are complete and accurate with respect to the
undersigned as a Purchaser; 

  

	(ii)	 that certain Amended and Restated Voting Agreement, dated as of November 9, 2018, by and among the Company
and the Stockholders (as defined therein), as amended from time to time (the “Voting Agreement”), as an “Investor” and a “Stockholder” thereunder; 

 

	(iii)	 that certain Amended and Restated Investors’ Rights Agreement, dated as of November 9, 2018, by and
among the Company and the Investors (as defined therein), as amended by Amendment No. 1, dated January 4, 2019 and Amendment No. 2, dated as of the date hereof, and as further amended from time to time (the “Rights
Agreement”), as an “Investor” thereunder; and 

  

	(iv)	 that certain Amended and Restated Right of First Refusal and Co-Sale
Agreement, dated as of November 9, 2018, by and among the Company, the Investors (as defined therein) and the Key Holders (as defined therein), as amended by Amendment No. 1, dated as of the date hereof, and as further amended from time to
time (the “Co-Sale Agreement”), as an “Investor” thereunder. 

The undersigned hereby authorizes this signature page to be attached to the Purchase Agreement, the Voting Agreement, the Rights Agreement and
the Co-Sale Agreement or counterparts thereof. The undersigned has carefully read each of the agreements listed above, including without limitation the representations and warranties of the Purchasers in
Section 3 of the Purchase Agreement. 
  

							
	INVESTOR:	 		 	Number of Shares
335,435                                        

			
	ADRIENNE PARDO	 		 	Aggregate Purchase Price: $499,999.42                  
			
	 /s/ Adrienne Pardo
	 		 	
	Adrienne Pardo	 		 	
			
	Address: [**]	 		 	
			
	AGREED TO AND ACCEPTED:	 		 	
			
	SCHRÖDINGER, INC.	 		 	
				
	By:	 	 /s/ Ramy Farid
	 		 	
	Name: Ramy Farid	 		 	
	Title: President and Chief Executive Officer	 		 	
			
	Date: April 8, 2019	 		 	

 SCHRÖDINGER, INC. 

Counterpart Signature Page 

to 
 Series E Preferred Stock
Financing Documents 
 By executing and delivering this signature page, the undersigned hereby joins in, becomes a party to and agrees
to be bound by the terms and conditions of: 
  

	(i)	 that certain Series E Preferred Stock Purchase Agreement, dated as of November 9, 2018, by and among
Schrödinger, Inc., a Delaware corporation (the “Company”), and the Purchasers named therein, as amended by Amendment No. 1, dated as of the date hereof, and as further amended from time to time (the “Purchase
Agreement”), as a “Purchaser” thereunder and acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers,” and hereby represents that the
statements contained therein are complete and accurate with respect to the undersigned as a Purchaser; 

  

	(ii)	 that certain Amended and Restated Voting Agreement, dated as of November 9, 2018, by and among the Company
and the Stockholders (as defined therein), as amended from time to time (the “Voting Agreement”), as an “Investor” and a “Stockholder” thereunder; 

 

	(iii)	 that certain Amended and Restated Investors’ Rights Agreement, dated as of November 9, 2018, by and
among the Company and the Investors (as defined therein), as amended by Amendment No. 1, dated January 4, 2019 and Amendment No. 2, dated April 8, 2019, and as further amended from time to time (the “Rights
Agreement”), as an “Investor” thereunder; and 

  

	(iv)	 that certain Amended and Restated Right of First Refusal and Co-Sale
Agreement, dated as of November 9, 2018, by and among the Company, the Investors (as defined therein) and the Key Holders (as defined therein), as amended by Amendment No. 1, dated April 8, 2019, and as further amended from time to
time (the “Co-Sale Agreement”), as an “Investor” thereunder. 

The undersigned hereby authorizes this signature page to be attached to the Purchase Agreement, the Voting Agreement, the Rights Agreement and
the Co-Sale Agreement or counterparts thereof. The undersigned has carefully read each of the agreements listed above, including without limitation the representations and warranties of the Purchasers in
Section 3 of the Purchase Agreement. 
  

							
	INVESTORS:	 		 	Number of Shares
6,708,707                                        

			
	ARTAL INTERNATIONAL S.C.A	 		 	Aggregate Purchase Price: $9,999,998.66                    
			
	By: Artal International Management SA, Its Managing Partner	 		 	
				
	By:	 	 /s/ Anne Goffard
	 		 	
	Name: Anne Goffard	 		 	
	Title: Managing Director	 		 	
	Address: [**]	 		 	
			
	AGREED TO AND ACCEPTED:	 		 	
			
	SCHRÖDINGER, INC.	 		 	
				
	By:	 	 /s/ Ramy Farid
	 		 	
	Name: Ramy Farid	 		 	
	Title: President and Chief Executive Officer	 		 	
	Date: April 26, 2019	 		 	
		 		 		 	
		 		 		 	

 SCHRÖDINGER, INC. 

Counterpart Signature Page 

to 
 Series E Preferred Stock
Financing Documents 
 By executing and delivering this signature page, the undersigned hereby joins in, becomes a party to and agrees
to be bound by the terms and conditions of: 
  

	(i)	 that certain Series E Preferred Stock Purchase Agreement, dated as of November 9, 2018, by and among
Schrödinger, Inc., a Delaware corporation (the “Company”), and the Purchasers named therein, as amended by Amendment No. 1, dated as of the date hereof, and as further amended from time to time (the “Purchase
Agreement”), as a “Purchaser” thereunder and acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers,” and hereby represents that the
statements contained therein are complete and accurate with respect to the undersigned as a Purchaser; 

  

	(ii)	 that certain Amended and Restated Voting Agreement, dated as of November 9, 2018, by and among the Company
and the Stockholders (as defined therein), as amended from time to time (the “Voting Agreement”), as an “Investor” and a “Stockholder” thereunder; 

 

	(iii)	 that certain Amended and Restated Investors’ Rights Agreement, dated as of November 9, 2018, by and
among the Company and the Investors (as defined therein), as amended by Amendment No. 1, dated January 4, 2019 and Amendment No. 2, dated April 8, 2019, and as further amended from time to time (the “Rights
Agreement”), as an “Investor” thereunder; and 

  

	(iv)	 that certain Amended and Restated Right of First Refusal and Co-Sale
Agreement, dated as of November 9, 2018, by and among the Company, the Investors (as defined therein) and the Key Holders (as defined therein), as amended by Amendment No. 1, dated April 8, 2019, and as further amended from time to
time (the “Co-Sale Agreement”), as an “Investor” thereunder. 

The undersigned hereby authorizes this signature page to be attached to the Purchase Agreement, the Voting Agreement, the Rights Agreement and
the Co-Sale Agreement or counterparts thereof. The undersigned has carefully read each of the agreements listed above, including without limitation the representations and warranties of the Purchasers in
Section 3 of the Purchase Agreement. 
  

							
	INVESTOR:	 		 	Number of Shares 218,033                        
			
	 /s/ Andrew E. Beck
	 		 	Aggregate Purchase Price: $324,999,99
	Andrew E. Beck	 		 	
	Address: [**]	 		 	
			
	AGREED TO AND ACCEPTED:	 		 	
			
	SCHRÖDINGER, INC.	 		 	
				
	By:	 	 /s/ Ramy Farid
	 		 	
	Name: Ramy Farid	 		 	
	Title: President and Chief Executive Officer	 		 	
			
	Date: April 26, 2019	 		 	

 SCHRÖDINGER, INC. 

Counterpart Signature Page 

to 
 Series E Preferred Stock
Financing Documents 
 By executing and delivering this signature page, the undersigned hereby joins in, becomes a party to and agrees
to be bound by the terms and conditions of: 
  

	(i)	 that certain Series E Preferred Stock Purchase Agreement, dated as of November 9, 2018, by and among
Schrödinger, Inc., a Delaware corporation (the “Company”), and the Purchasers named therein, as amended by Amendment No. 1, dated as of the date hereof, and as further amended from time to time (the “Purchase
Agreement”), as a “Purchaser” thereunder and acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers,” and hereby represents that the
statements contained therein are complete and accurate with respect to the undersigned as a Purchaser; 

  

	(ii)	 that certain Amended and Restated Voting Agreement, dated as of November 9, 2018, by and among the Company
and the Stockholders (as defined therein), as amended from time to time (the “Voting Agreement”), as an “Investor” and a “Stockholder” thereunder; 

 

	(iii)	 that certain Amended and Restated Investors’ Rights Agreement, dated as of November 9, 2018, by and
among the Company and the Investors (as defined therein), as amended by Amendment No. 1, dated January 4, 2019 and Amendment No. 2, dated April 8, 2019, and as further amended from time to time (the “Rights
Agreement”), as an “Investor” thereunder; and 

  

	(iv)	 that certain Amended and Restated Right of First Refusal and Co-Sale
Agreement, dated as of November 9, 2018, by and among the Company, the Investors (as defined therein) and the Key Holders (as defined therein), as amended by Amendment No. 1, dated April 8, 2019, and as further amended from time to
time (the “Co-Sale Agreement”), as an “Investor” thereunder. 

The undersigned hereby authorizes this signature page to be attached to the Purchase Agreement, the Voting Agreement, the Rights Agreement and
the Co-Sale Agreement or counterparts thereof. The undersigned has carefully read each of the agreements listed above, including without limitation the representations and warranties of the Purchasers in
Section 3 of the Purchase Agreement. 
  

							
			
	INVESTOR:	  		  	Number of Shares
1,341,741                                       
     
			
	TUBUS, LLC	  		  	Aggregate Purchase Price: $1,999,999.14                       
				
	By:	 	 /s/ Michael Antonov
	  		  	
	Name: Michael Antonov	  		  	
	Title: Manager	  		  	
	Address: [**]	  		  	
			
	AGREED TO AND ACCEPTED:	  		  	
			
	SCHRÖDINGER, INC.	  		  	
				
	By:	 	 /s/ Ramy Farid
	  		  	
	Name: Ramy Farid	  		  	
	Title: President and Chief Executive Officer	  		  	
			
	Date: April 26, 2019	  		  	

 SCHRÖDINGER, INC. 

Counterpart Signature Page 

to 
 Series E Preferred Stock
Financing Documents 
 By executing and delivering this signature page, the undersigned hereby joins in, becomes a party to and agrees
to be bound by the terms and conditions of: 
  

	(i)	 that certain Series E Preferred Stock Purchase Agreement, dated as of November 9, 2018, by and among
Schrödinger, Inc., a Delaware corporation (the “Company”), and the Purchasers named therein, as amended by Amendment No. 1, dated as of April 26, 2019, and as further amended from time to time (the “Purchase
Agreement”), as a “Purchaser” thereunder and acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of the Purchasers,” and hereby represents that the
statements contained therein are complete and accurate with respect to the undersigned as a Purchaser; 

  

	(ii)	 that certain Amended and Restated Voting Agreement, dated as of November 9, 2018, by and among the Company
and the Stockholders (as defined therein), as amended from time to time (the “Voting Agreement”), as an “Investor” and a “Stockholder” thereunder; 

 

	(iii)	 that certain Amended and Restated Investors’ Rights Agreement, dated as of November 9, 2018, by and
among the Company and the Investors (as defined therein), as amended by Amendment No. 1, dated January 4, 2019 and Amendment No. 2, dated April 8, 2019, and as further amended from time to time (the “Rights
Agreement”), as an “Investor” thereunder; and 

  

	(iv)	 that certain Amended and Restated Right of First Refusal and Co-Sale
Agreement, dated as of November 9, 2018, by and among the Company, the Investors (as defined therein) and the Key Holders (as defined therein), as amended by Amendment No. 1, dated April 8, 2019, and as further amended from time to
time (the “Co-Sale Agreement”), as an “Investor” thereunder. 

The undersigned hereby authorizes this signature page to be attached to the Purchase Agreement, the Voting Agreement, the Rights Agreement and
the Co-Sale Agreement or counterparts thereof. The undersigned has carefully read each of the agreements listed above, including without limitation the representations and warranties of the Purchasers in
Section 3 of the Purchase Agreement. 
  

							
	INVESTOR:	 		 	Number of Shares
3,354,353                                    
			
	QUANTUM DISCOVERY LP	 		 	Aggregate Purchase Price: $4,999,998.59               

							
				
	By:	 	 /s/ Jian Guo
                            /s/ Feng Zu
	 		 	

							
	Name:	 	Jian Guo                              Feng Zu	 		 	
	Title:	 	President                             Secretary	 		 	
	Address: [**]	 		 	
			
	AGREED TO AND ACCEPTED:	 		 	
			
	SCHRÖDINGER, INC.	 		 	
				
	By:	 	 /s/ Ramy Farid
	 		 	
	Name: Ramy Farid	 		 	
	Title: President and Chief Executive Officer	 		 	
			
	Date: May 6, 2019	 		 	

 SCHRÖDINGER, INC. 

Counterpart Signature Page 

to 
 Series E Preferred Stock
Financing Documents 
 By executing and delivering this signature page, the undersigned hereby joins in, becomes a party to and agrees
to be bound by the terms and conditions of: 
  

	(i)	 that certain Series E Preferred Stock Purchase Agreement, dated as of November 9, 2018, by and among
Schrödinger, Inc., a Delaware corporation (the “Company”), and the Purchasers named therein, as amended by Amendment No. 1, dated as of April 26, 2019 and Amendment No. 2, dated as of the date hereof, and as
further amended from time to time (the “Purchase Agreement”), as a “Purchaser” thereunder and acknowledges having read the representations in the Purchase Agreement section entitled “Representations and Warranties of
the Purchasers,” and hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Purchaser; 

  

	(ii)	 that certain Amended and Restated Voting Agreement, dated as of November 9, 2018, by and among the Company
and the Stockholders (as defined therein), as amended from time to time (the “Voting Agreement”), as an “Investor” and a “Stockholder” thereunder; 

 

	(iii)	 that certain Amended and Restated Investors’ Rights Agreement, dated as of November 9, 2018, by and
among the Company and the Investors (as defined therein), as amended by Amendment No. 1, dated January 4, 2019 and Amendment No. 2, dated April 8, 2019, and as further amended from time to time (the “Rights
Agreement”), as an “Investor” thereunder; and 

  

	(iv)	 that certain Amended and Restated Right of First Refusal and Co-Sale
Agreement, dated as of November 9, 2018, by and among the Company, the Investors (as defined therein) and the Key Holders (as defined therein), as amended by Amendment No. 1, dated April 8, 2019, and as further amended from time to
time (the “Co-Sale Agreement”), as an “Investor” thereunder. 

The undersigned hereby authorizes this signature page to be attached to the Purchase Agreement, the Voting Agreement, the Rights Agreement and
the Co-Sale Agreement or counterparts thereof. The undersigned has carefully read each of the agreements listed above, including without limitation the representations and warranties of the Purchasers in
Section 3 of the Purchase Agreement. 
  

							
	INVESTOR:	 		 	Number of Shares
1,459,143                                       
 
			
	LAURION CAPITAL MASTER FUND LTD	 		 	Aggregate Purchase Price: $2,174,998.56                   

							
				
	By:	 	 /s/ Jason Riesel
                        /s/ Mosih Mohebbi
	 		 	

							
	Name:	 	Jason Riesel                             Mosih Mohebbi	 		 	
	Title:	 	GC and CCO                           CFO	 		 	
	Address: [**]	 		 	
			
	AGREED TO AND ACCEPTED:	 		 	
			
	SCHRÖDINGER, INC.	 		 	
				
	By:	 	 /s/ Ramy Farid
	 		 	
	Name: Ramy Farid	 		 	
	Title: President and Chief Executive Officer	 		 	
			
	Date: May 14, 2019	 		 	

 SCHEDULE A 

Investors 
 David E. Shaw 

D.E. Shaw & Co., L.P. 
 D.E. Shaw Valence Portfolios, LLC

 D.E. Shaw Technology Development, LLC 
 The Bill and Melinda
Gates Foundation Trust 
 Scott Becker 
 Trustees of the
University of Columbia 
 Benjamin Appen 
 Richard E. Appen 

Louis Salkind 
 Andrew E. Trey Beck III 

Erick Wepsic 
 Eric S. Robinson 

Julius Gaudio 
 Yuan Chang and Mary H. Chang Family Irrevocable
Trust 
 Martin Fleisher 
 Stuart Steckler 

Suzanne L. Telsey 
 Deerfield Private Design Fund IV, L.P. 

WuXi PharmaTech Healthcare Fund I L.P. 
 Baron Growth Fund 

Qiming Venture Partners VI, L.P. 
 Qiming Managing Directors Fund
VI, L.P. 
 GV 2019, L.P. 
 Pav Investments Pte. Ltd. 

Adrienne Pardo 
 Artal International S.C.A 

Tubus, LLC 
 Quantum Discovery LP 

Laurion Capital Master Fund Ltd. 

 SCHRÖDINGER, INC. 

AMENDMENT NO. 1 
 TO 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

This AMENDMENT NO. 1 TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Amendment”), effective as of January 4,
2019, amends that certain Amended and Restated Investors’ Rights Agreement, dated as of November 9, 2018, by and among Schrödinger, Inc. (the “Company”) and the Investors identified therein (the “IRA”). Capitalized
terms used and not defined herein shall have the meanings set forth in the IRA. 
 WHEREAS, pursuant to Section 1.3 of the Series E
Preferred Stock Purchase Agreement, dated November 9, 2018, by and among the Company and the parties named therein, the Company intends to sell and GV 2019, L.P. (“GV”) intends to purchase 3,354,353 shares of Series E Preferred Stock
(the “Shares”) of the Company in an additional closing (the “Additional Closing”); 
 WHEREAS, in connection with
GV’s purchase of the Shares in the Additional Closing, GV desires to have all of the same benefits and rights as a “Major Investor” under the IRA so long as GV, collectively with its Affiliates, holds all of the Shares purchased by GV
at the Additional Closing; 
 WHEREAS, the Company and the Investors desire to amend the IRA to reflect the foregoing; and 

WHEREAS, Section 6.6 of the IRA provides in part that any term of the IRA may be amended with the written consent of (i) the Company
and (ii) the holders of 70% of the Registrable Securities then outstanding; provided further that any section of the IRA applicable to Major Investors may not be amended without the written consent of the holders of a majority of the
Registrable Securities then held by the Major Investors (collectively, the “Requisite Parties”); 
 NOW, THEREFORE, in
consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the undersigned, who constitute the Requisite Parties, hereby agree as
follows: 
 1. Amendment to Definitions. The definition of “Major Investor” in Section 1 of the IRA is hereby deleted
in its entirety, and the following is inserted in lieu thereof: 
 ““Major Investor” means (i) any Investor that,
individually or together with such Investor’s Affiliates, holds at least 15,902,140 shares of Preferred Stock (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date
hereof); (ii) Deerfield Private Design Fund IV, L.P. (“Deerfield”) for so long as Deerfield holds at least seventy percent (70%) of the shares of Series E 

 
Preferred Stock originally sold to it under the Purchase Agreement (as adjusted for any stock split, stock dividend, combination or other recapitalization or reclassification effected after the
date hereof); (iii) WuXi PharmaTech Healthcare Fund I L.P. (“WuXi”) for so long as WuXi holds all of the shares of Series E Preferred Stock originally sold to it under the Purchase Agreement (as adjusted for any stock split, stock
dividend, combination or other recapitalization or reclassification effected after the date hereof); (iv) Qiming Venture Partners VI, L.P. and Qiming Managing Directors Fund VI, L.P. (collectively, “Qiming”) for so long as Qiming
holds all of the shares of Series E Preferred Stock originally sold to it under the Purchase Agreement (as adjusted for any stock split, stock dividend, combination or other recapitalization or reclassification effected after the date hereof); (v)
Baron Growth Fund (“Baron”) for so long as Baron holds all of the shares of Series E Preferred Stock originally sold to it under the Purchase Agreement (as adjusted for any stock split, stock dividend, combination or other
recapitalization or reclassification effected after the date hereof); and (vi) GV 2019, L.P. (“GV”) for so long as GV, collectively with its Affiliates, holds all of the shares of Series E Preferred Stock originally sold to it
under the Purchase Agreement (as adjusted for any stock split, stock dividend, combination or other recapitalization or reclassification effected after the date hereof). For the avoidance of any doubt, in no event shall Scott Becker be deemed a
Major Investor.” 
 2. Amendment to Section 6.6. The first sentence of Section 6.6 of the IRA is hereby
deleted in its entirety, and the following is inserted in lieu thereof. 
 “6.6 Amendments and Waivers. Any term of this
Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of at
least seventy percent (70%) of the Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Section 2.12(c); provided further that any provision hereof may be waived by any waiving
party on such party’s own behalf, without the consent of any other party; provided, further, that (A) romanette (ii) in the definition of “Major Investor” set forth in Section 1 of this Agreement and this proviso
(A) may not be amended or waived without the consent of Deerfield; (B) romanette (iii) in the definition of “Major Investor” set forth in Section 1 of this Agreement, Section 3.3(b) of this Agreement and this proviso
(B) may not be amended or waived without the consent of WuXi; (C) romanette (iv) in the definition of “Major Investor” set forth in Section 1 of this Agreement and this proviso (C) may not be amended or waived without
the consent of Qiming; (D) romanette (v) in the definition of “Major Investor” set forth in Section 1 of this Agreement and this proviso (D) may not be amended or waived without the consent of Baron; and (E) romanette
(vi) in the definition of “Major Investor” set forth in Section 1 of this Agreement and this proviso (E) may not be amended or waived without the consent of GV. 

3. Entire Agreement. The IRA, as amended by this Amendment, contains the entire agreement among the parties with respect to the subject
matter thereof and amends, restates and supersedes all prior and contemporaneous arrangements or understandings with respect thereto. 

  
 - 2 - 

 4. Effectiveness. This Amendment shall be effective upon the Additional Closing. Upon
the effectiveness of this Amendment, on and after the date hereof, each reference in the IRA to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import, and each reference in the other
documents entered into in connection with the IRA, shall mean and be a reference to the IRA, as amended hereby. All terms in the IRA that are not explicitly amended by this Amendment shall remain in full force and effect and are hereby ratified and
confirmed. 
 5. Governing Law. This Amendment shall be governed by, and construed in accordance with, the laws of the State of
Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of law. 
 6. Counterpart Signature
Pages. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail
(including pdf or any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and
be valid and effective for all purposes. 
 [Remainder of Page Intentionally Left Blank] 

  
 - 3 - 

 IN WITNESS WHEREOF, this Amendment has been executed by the parties hereto
as of the day and year first above written. 
  

			
	SCHRÖDINGER, INC.
		
	By:	 	 /s/ Ramy Farid

	Name: Ramy Farid
	Title: President and Chief Executive Officer
	
	INVESTORS:
	
	BILL & MELINDA GATES FOUNDATION TRUST
		
	By:	 	 /s/ Alan Heuberger

	Name: Alan Heuberger
	Title: Authorized Representative
	
	 /s/ David E. Shaw

	David E. Shaw

 [Signature Page to Amendment No. 1 to Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, this Amendment has been executed by the parties hereto
as of the day and year first above written. 
  

			
	WUXI PHARMATECH HEALTHCARE FUND I L.P.
		
	By:	 	 /s/ Edward Hu

	Name: Edward Hu
	Title: Authorized Representative
	
	BARON GROWTH FUND
		
	By:	 	 /s/ Patrick M. Patalino

	Name: Patrick M. Patalino
	Title: General Counsel
	
	DEERFIELD PRIVATE DESIGN FUND IV, L.P.
	
	By: Deerfield Mgmt IV, L.P., its General Partner
	
	By: J.E. Flynn Capital IV, L.P., its General Partner
		
	By:	 	          

	Name:	 	
	Title: Authorized Signatory

 [Signature Page to Amendment No. 1 to Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, this Amendment has been executed by the parties hereto
as of the day and year first above written. 
  

					
	QIMING VENTURE PARTNERS VI, L.P.,
	a Cayman Islands exempted limited partnership
		
	        	 	By: QIMING GP VI, L.P. a Cayman Islands        exempted limited partnership
		
		 	Its: General Partner
			
		 	        By:	 	QIMING CORPORATE GP VI, LTD. a Cayman Islands exempted company
			
		 	        Its:	 	General Partner
			
		 	        By:	 	 /s/ Robert Headley

		 	        Its:	 	Authorized Signatory
	
	QIMING MANAGING DIRECTORS FUND VI, L.P., a Cayman Islands exempted limited partnership
		
		 	By: QIMING CORPORATE GP VI, LTD., a        Cayman Islands exempted company
		
		 	Its: General Partner
			
		 	        By:	 	 /s/ Robert Headley

		 	        Its:	 	Authorized Signatory
		
		 	        Signing Location: Bellevue, WA USA          
		
		 	        Signature of Witness: /s/ Laura Brakus        
		
		 	        Name of Witness: Laura Brakus                   
 

 [Signature Page to Amendment No. 1 to Amended and Restated Investors’ Rights Agreement] 

 

 SCHRÖDINGER, INC. 

AMENDMENT NO. 2 
 TO 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

This AMENDMENT NO. 2 TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Amendment”), effective as of April 8,
2019, amends that certain Amended and Restated Investors’ Rights Agreement, dated as of November 9, 2018, by and among Schrödinger, Inc. (the “Company”) and the Investors identified therein, as amended by Amendment
No. 1 to the Amended and Restated Investor’s Rights Agreement, dated January 4, 2019 (as so amended, the “IRA”). Capitalized terms used and not defined herein shall have the meanings set forth in the IRA. 

WHEREAS, pursuant to Section 1.3 of the Series E Preferred Stock Purchase Agreement, dated November 9, 2018, by and among the
Company and the parties named therein, the Company intends to sell and Pav Investments Pte. Ltd. (“Pavilion”) intends to purchase 3,354,353 shares of Series E Preferred Stock (the “Shares”) of the Company in an additional closing
(the “Additional Closing”); 
 WHEREAS, in connection with Pavilion’s purchase of the Shares in the Additional Closing,
Pavilion desires to have all of the same benefits and rights as a “Major Investor” under the IRA so long as Pavilion, collectively with its Affiliates, holds all of the Shares purchased by Pavilion at the Additional Closing; 

WHEREAS, the Company and the Investors desire to amend the IRA to reflect the foregoing; and 

WHEREAS, Section 6.6 of the IRA provides in part that any term of the IRA may be amended with the written consent of (i) the Company
and (ii) the holders of 70% of the Registrable Securities then outstanding; provided further that any section of the IRA applicable to Major Investors may not be amended without the written consent of the holders of a majority of the
Registrable Securities then held by the Major Investors (collectively, the “Requisite Parties”); 
 NOW, THEREFORE, in
consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the undersigned, who constitute the Requisite Parties, hereby agree as
follows: 
 1. Amendment to Definitions. The definition of “Major Investor” in Section 1 of the IRA is hereby deleted
in its entirety, and the following is inserted in lieu thereof: 
 ““Major Investor” means (i) any Investor that,
individually or together with such Investor’s Affiliates, holds at least 15,902,140 shares of Preferred Stock (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after

 
the date hereof); (ii) Deerfield Private Design Fund IV, L.P. (“Deerfield”) for so long as Deerfield holds at least seventy percent (70%) of the shares of Series E Preferred
Stock originally sold to it under the Purchase Agreement (as adjusted for any stock split, stock dividend, combination or other recapitalization or reclassification effected after the date hereof); (iii) WuXi PharmaTech Healthcare Fund I L.P.
(“WuXi”) for so long as WuXi holds all of the shares of Series E Preferred Stock originally sold to it under the Purchase Agreement (as adjusted for any stock split, stock dividend, combination or other recapitalization or
reclassification effected after the date hereof); (iv) Qiming Venture Partners VI, L.P. and Qiming Managing Directors Fund VI, L.P. (collectively, “Qiming”) for so long as Qiming holds all of the shares of Series E Preferred Stock
originally sold to it under the Purchase Agreement (as adjusted for any stock split, stock dividend, combination or other recapitalization or reclassification effected after the date hereof); (v) Baron Growth Fund (“Baron”) for so
long as Baron holds all of the shares of Series E Preferred Stock originally sold to it under the Purchase Agreement (as adjusted for any stock split, stock dividend, combination or other recapitalization or reclassification effected after the date
hereof); (vi) GV 2019, L.P. (“GV”) for so long as GV, collectively with its Affiliates, holds all of the shares of Series E Preferred Stock originally sold to it under the Purchase Agreement (as adjusted for any stock split, stock
dividend, combination or other recapitalization or reclassification effected after the date hereof); and (vii) Pav Investments Pte. Ltd. (“Pavilion”) for so long as Pavilion holds all of the shares of Series E Preferred Stock
originally sold to it under the Purchase Agreement (as adjusted for any stock split, stock dividend, combination or other recapitalization or reclassification effected after the date hereof). For the avoidance of any doubt, in no event shall Scott
Becker be deemed a Major Investor.” 
 2. Amendment to Section 6.6. The first sentence of Section 6.6 of
the IRA is hereby deleted in its entirety, and the following is inserted in lieu thereof: 
 “6.6 Amendments and
Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the
Company and the holders of at least seventy percent (70%) of the Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Section 2.12(c); provided further that any provision hereof may
be waived by any waiving party on such party’s own behalf, without the consent of any other party; provided, further, that (A) romanette (ii) in the definition of “Major Investor” set forth in Section 1 of this Agreement and
this proviso (A) may not be amended or waived without the consent of Deerfield; (B) romanette (iii) in the definition of “Major Investor” set forth in Section 1 of this Agreement, Section 3.3(b) of this Agreement and
this proviso (B) may not be amended or waived without the consent of WuXi; (C) romanette (iv) in the definition of “Major Investor” set forth in Section 1 of this Agreement and this proviso (C) may not be amended or
waived without the consent of Qiming; (D) romanette (v) in the definition of “Major Investor” set forth in Section 1 of this Agreement and this proviso (D) may not be amended or waived without the consent of Baron;
(E) romanette (vi) in the definition of “Major Investor” set forth in Section 1 of this Agreement and this proviso (E) may not be amended or waived without the consent of GV; and (F) romanette (vii) in the definition of
“Major Investor” set forth in Section 1 of this Agreement and this proviso (F) may not be amended or waived without the consent of Pavilion. 

  
 - 2 - 

 3. Entire Agreement. The IRA, as amended by this Amendment, contains the entire
agreement among the parties with respect to the subject matter thereof and amends, restates and supersedes all prior and contemporaneous arrangements or understandings with respect thereto. 

4. Effectiveness. This Amendment shall be effective upon the Additional Closing. Upon the effectiveness of this Amendment, on and after
the date hereof, each reference in the IRA to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import, and each reference in the other documents entered into in connection with the IRA, shall
mean and be a reference to the IRA, as amended hereby. All terms in the IRA that are not explicitly amended by this Amendment shall remain in full force and effect and are hereby ratified and confirmed. 

5. Governing Law. This Amendment shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless
of the laws that might otherwise govern under applicable principles of conflicts of law. 
 6. Counterpart Signature Pages. This
Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or
any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and
effective for all purposes. 
 [Remainder of Page Intentionally Left Blank] 

 

  
 - 3 - 

 IN WITNESS WHEREOF, this Amendment has been executed by the parties hereto as of the day and
year first above written. 
  

			
	SCHRÖDINGER, INC.
		
	By:	 	 /s/ Ramy Farid

	Name:	 	Ramy Farid
	Title:	 	President and Chief Executive Officer
	
	INVESTORS
	
	BILL & MELINDA GATES FOUNDATION TRUST
		
	By:	 	 /s/ Alan Heuberger

	Name:	 	Alan Heuberger
	Title:	 	Authorized Representative
	
	 /s/ David E. Shaw

	David E. Shaw

 IN WITNESS WHEREOF, this Amendment has been executed by the parties hereto as of the day and
year first above written. 
  

			
	WUXI PHARMATECH HEALTHCARE FUND I L.P.
		
	By:	 	 /s/ Edward Hu

	Name:	 	Edward Hu
	Title:	 	Authorized Signatory
	
	BARON GROWTH FUND
		
	By:	 	 /s/ Patrick M. Patalino

	Name:	 	Patrick M. Patalino
	Title:	 	General Counsel
	
	DEERFIELD PRIVATE DESIGN FUND IV, L.P.
	
	By: Deerfield Mgmt IV, L.P., its General Partner
	
	By: J. E. Flynn Capital IV, L.P., its General Partner
		
	By:	 	  

	Name:	 	
	Title:	 	Authorized Signatory

 IN WITNESS WHEREOF, this Amendment has been executed by the parties hereto as of the day and
year first above written. 
  

			
	GV 2019, L.P.
	
	By: GV 2019 GP, L.P., its General Partner
	By: GV 2019 GP, L.L.C., its General Partner
		
	By:	 	 /s/ Daphne M. Chang

	Name:	 	Daphne M. Chang
	Title:	 	Authorized SignatoryEX-10.2

 Exhibit 10.2 

SCHRöDINGER, INC. 

2010 STOCK PLAN 

ADOPTED ON OCTOBER 28, 2010 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 SECTION 1.
	 	ESTABLISHMENT AND PURPOSE	  	 	1	 
			
	 SECTION 2.
	 	ADMINISTRATION	  	 	1	 
	 (a)
	 	Committees of the Board of Directors	  	 	1	 
	 (b)
	 	Authority of the Board of Directors	  	 	1	 
			
	 SECTION 3.
	 	ELIGIBILITY	  	 	1	 
	 (a)
	 	General Rule	  	 	1	 
	 (b)
	 	Ten-Percent Stockholders	  	 	1	 
			
	 SECTION 4.
	 	STOCK SUBJECT TO PLAN	  	 	2	 
	 (a)
	 	Basic Limitation	  	 	2	 
	 (b)
	 	Additional Shares	  	 	2	 
			
	 SECTION 5.
	 	TERMS AND CONDITIONS OF AWARDS OR SALES	  	 	2	 
	 (a)
	 	Stock Grant or Purchase Agreement	  	 	2	 
	 (b)
	 	Duration of Offers and Nontransferability of Rights	  	 	2	 
	 (c)
	 	Purchase Price	  	 	2	 
	 (d)
	 	Withholding Taxes	  	 	2	 
	 (e)
	 	Transfer Restrictions and Forfeiture Conditions	  	 	3	 
			
	 SECTION 6.
	 	TERMS AND CONDITIONS OF OPTIONS	  	 	3	 
	 (a)
	 	Stock Option Agreement	  	 	3	 
	 (b)
	 	Number of Shares	  	 	3	 
	 (c)
	 	Exercise Price	  	 	3	 
	 (d)
	 	Exercisability	  	 	3	 
	 (e)
	 	Term	  	 	3	 
	 (f)
	 	Post-Exercise Restrictions on Transfer of Shares	  	 	3	 
	 (g)
	 	Pre-Exercise Restrictions on Transfer of Options or Shares	  	 	4	 
	 (h)
	 	Withholding Taxes	  	 	4	 
	 (i)
	 	No Rights as a Stockholder	  	 	4	 
	 (j)
	 	Modification, Extension and Assumption of Options	  	 	4	 
	 (k)
	 	Company’s Right to Cancel Certain Options	  	 	5	 
			
	 SECTION 7.
	 	PAYMENT FOR SHARES	  	 	5	 
	 (a)
	 	General Rule	  	 	5	 
	 (b)
	 	Services Rendered	  	 	5	 
	 (c)
	 	Promissory Note	  	 	5	 
	 (d)
	 	Surrender of Stock	  	 	5	 
	 (e)
	 	Exercise/Sale	  	 	5	 
	 (f)
	 	Other Forms of Payment	  	 	5	 
			
	 SECTION 8.
	 	ADJUSTMENT OF SHARES	  	 	6	 
	 (a)
	 	General	  	 	6	 

							
	 (b)
	 	Mergers and Consolidations	  	 	6	 
	 (c)
	 	Reservation of Rights	  	 	7	 
			
	 SECTION 9.
	 	PRE-EXERCISE INFORMATION REQUIREMENT	  	 	7	 
	 (a)
	 	Application of Requirement	  	 	7	 
	 (b)
	 	Scope of Requirement	  	 	7	 
			
	 SECTION 10.
	 	MISCELLANEOUS PROVISIONS	  	 	7	 
	 (a)
	 	Securities Law Requirements	  	 	7	 
	 (b)
	 	No Retention Rights	  	 	7	 
	 (c)
	 	Treatment as Compensation	  	 	8	 
	 (d)
	 	Governing Law	  	 	8	 
			
	 SECTION 11.
	 	DURATION AND AMENDMENTS	  	 	8	 
	 (a)
	 	Term of the Plan	  	 	8	 
	 (b)
	 	Right to Amend or Terminate the Plan	  	 	8	 
	 (c)
	 	Effect of Amendment or Termination	  	 	8	 
			
	 SECTION 12.
	 	DEFINITIONS	  	 	8	 

 SCHRöDINGER, INC. 2010
STOCK PLAN 
 SECTION 1. ESTABLISHMENT AND PURPOSE. 

The purpose of the Plan is to offer selected persons an opportunity to acquire a proprietary interest in the success of the Company, or to
increase such interest, by acquiring Shares of the Company’s Stock. The Plan provides both for the direct award or sale of Shares and for the grant of Options to purchase Shares. Options granted under the Plan may include Nonstatutory Options
as well as ISOs intended to qualify under Section 422 of the Code. 
 Capitalized terms are defined in Section 12. 

SECTION 2. ADMINISTRATION. 
 (a)
Committees of the Board of Directors. The Plan may be administered by one or more Committees. Each Committee shall consist of one or more members of the Board of Directors who have been appointed by the Board of Directors. Each
Committee shall have such authority and be responsible for such functions as the Board of Directors has assigned to it. If no Committee has been appointed, the entire Board of Directors shall administer the Plan. Any reference to the Board of
Directors in the Plan shall be construed as a reference to the Committee (if any) to whom the Board of Directors has assigned a particular function. 

(b) Authority of the Board of Directors. Subject to the provisions of the Plan, the Board of Directors shall have full
authority and discretion to take any actions it deems necessary or advisable for the administration of the Plan. All decisions, interpretations and other actions of the Board of Directors shall be final and binding on all Purchasers, all Optionees
and all persons deriving their rights from a Purchaser or Optionee. 
 SECTION 3. ELIGIBILITY. 

(a) General Rule. Only Employees, Outside Directors and Consultants shall be eligible for the grant of Nonstatutory
Options or the direct award or sale of Shares. Only Employees shall be eligible for the grant of ISOs. 
 (b) Ten-Percent Stockholders. A person who owns more than 10% of the total combined voting power of all classes of outstanding stock of the Company, its Parents or any of its Subsidiaries shall not be eligible
for the grant of an ISO unless (i) the Exercise Price is at least 110% of the Fair Market Value of a Share on the Date of Grant and (ii) such ISO by its terms is not exercisable after the expiration of five years from the Date of Grant.
For purposes of this Subsection (b), in determining stock ownership, the attribution rules of Section 424(d) of the Code shall be applied. 

  
 1 

 SECTION 4. STOCK SUBJECT TO PLAN. 

(a) Basic Limitation. Not more than 3,160,000 Shares may be issued under the Plan, subject to Subsection (b) below
and Section 8(a).1 Any or all of these Shares may be issued upon the exercise of ISOs. The number of Shares that are subject to Options or other rights outstanding at any time under the Plan
shall not exceed the number of Shares that then remain available for issuance under the Plan. The Company, during the term of the Plan, shall at all times reserve and keep available sufficient Shares to satisfy the requirements of the Plan. Shares
offered under the Plan may be authorized but unissued Shares or treasury Shares. 
 (b) Additional Shares. In the event
that Shares previously issued under the Plan are reacquired by the Company, such Shares shall be added to the number of Shares then available for issuance under the Plan. In the event that Shares that otherwise would have been issuable under the
Plan are withheld by the Company in payment of the Purchase Price, Exercise Price or withholding taxes, such Shares shall remain available for issuance under the Plan. In the event that an outstanding Option or other right for any reason expires or
is canceled, the Shares allocable to the unexercised portion of such Option or other right shall be added to the number of Shares then available for issuance under the Plan. 

SECTION 5. TERMS AND CONDITIONS OF AWARDS OR SALES. 

(a) Stock Grant or Purchase Agreement. Each award of Shares under the Plan shall be evidenced by a Stock Grant Agreement between the
Grantee and the Company. Each sale of Shares under the Plan (other than upon exercise of an Option) shall be evidenced by a Stock Purchase Agreement between the Purchaser and the Company. Such award or sale shall be subject to all applicable terms
and conditions of the Plan and may be subject to any other terms and conditions which are not inconsistent with the Plan and which the Board of Directors deems appropriate for inclusion in a Stock Grant Agreement or Stock Purchase Agreement. The
provisions of the various Stock Grant Agreements and Stock Purchase Agreements entered into under the Plan need not be identical. 

(b) Duration of Offers and Nontransferability of Rights. Any right to purchase Shares under the Plan (other than an
Option) shall automatically expire if not exercised by the Purchaser within 30 days after the grant of such right was communicated to the Purchaser by the Company. Such right shall not be transferable and shall be exercisable only by the Purchaser
to whom such right was granted. 
 (c) Purchase Price. The Board of Directors shall determine the Purchase Price of
Shares to be offered under the Plan at its sole discretion. The Purchase Price shall be payable in a form described in Section 7. 

(d) Withholding Taxes. As a condition to the award, purchase, vesting or transfer of Shares, the Grantee or Purchaser shall make such
arrangements as the Board of Directors may require for the satisfaction of any federal, state, local or foreign withholding tax obligations that may arise in connection with such event. 

 

	1 	 Please refer to Exhibit A for a schedule of the initial share reserve and any subsequent increases in the
reserve. 

  
 2 

 (e) Transfer Restrictions and Forfeiture Conditions. Any Shares awarded or sold under
the Plan shall be subject to such special forfeiture conditions, rights of repurchase, rights of first refusal and other transfer restrictions as the Board of Directors may determine. Such restrictions shall be set forth in the applicable Stock
Grant Agreement or Stock Purchase Agreement and shall apply in addition to any restrictions that may apply to holders of Shares generally. 
 SECTION 6.
TERMS AND CONDITIONS OF OPTIONS. 
 (a) Stock Option Agreement. Each grant of an Option under the Plan shall be
evidenced by a Stock Option Agreement between the Optionee and the Company. The Option shall be subject to all applicable terms and conditions of the Plan and may be subject to any other terms and conditions which are not inconsistent with the Plan
and which the Board of Directors deems appropriate for inclusion in a Stock Option Agreement. The provisions of the various Stock Option Agreements entered into under the Plan need not be identical. 

(b) Number of Shares. Each Stock Option Agreement shall specify the number of Shares that are subject to the Option and
shall provide for the adjustment of such number in accordance with Section 8. The Stock Option Agreement shall also specify whether the Option is an ISO or a Nonstatutory Option. 

(c) Exercise Price. Each Stock Option Agreement shall specify the Exercise Price. The Exercise Price of an Option shall
not be less than 100% of the Fair Market Value of a Share on the Date of Grant, and in the case of an ISO a higher percentage may be required by Section 3(b). Subject to the preceding sentence, the Exercise Price shall be determined by the
Board of Directors at its sole discretion. The Exercise Price shall be payable in a form described in Section 7. This Subsection (c) shall not apply to an Option granted pursuant to an assumption of, or substitution for, another option in
a manner that complies with Section 424(a) of the Code (whether or not the Option is an ISO). 
 (d)
Exercisability. Each Stock Option Agreement shall specify the date when all or any installment of the Option is to become exercisable. No Option shall be exercisable unless the Optionee (i) has delivered an executed copy of the
Stock Option Agreement to the Company or (ii) otherwise agrees to be bound by the terms of the Stock Option Agreement. The Board of Directors shall determine the exercisability provisions of the Stock Option Agreement at its sole discretion.

 (e) Term. The Stock Option Agreement shall specify the term of the Option. The term shall not exceed 10 years from
the Date of Grant, and in the case of an ISO a shorter term may be required by Section 3(b). Subject to the preceding sentence, the Board of Directors at its sole discretion shall determine when an Option is to expire. A Stock Option Agreement
may provide for expiration prior to the end of its term in the event of the termination of the Optionee’s Service or death. 

(f) Post-Exercise Restrictions on Transfer of Shares. Any Shares issued upon exercise of an Option shall be subject to
such special forfeiture conditions, rights of repurchase, rights of first refusal and other transfer restrictions as the Board of Directors may determine. Such restrictions shall be set forth in the applicable Stock Option Agreement and shall apply
in addition to any restrictions that may apply to holders of Shares generally. 

  
 3 

 (g) Pre-Exercise Restrictions on Transfer
of Options or Shares. An Option shall be transferable by the Optionee only by (i) a beneficiary designation, (ii) a will or (iii) the laws of descent and distribution, except as provided in the next sentence. If the
applicable Stock Option Agreement so provides, a Nonstatutory Option shall also be transferable by gift or domestic relations order to a Family Member of the Optionee. An ISO may be exercised during the lifetime of the Optionee only by the Optionee
or by the Optionee’s guardian or legal representative. In addition, an Option shall comply with all conditions of Rule 12h-1(f)(1) under the Exchange Act until the Company becomes subject to the
reporting requirements of Section 13 or 15(d) of the Exchange Act. Such conditions include, without limitation, the transferability restrictions set forth in Rule 12h-1(f)(1)(iv) and (v)
under the Exchange Act, which shall apply to an Option and, prior to exercise, to the Shares to be issued upon exercise of such Option during the period commencing on the Date of Grant and ending on the earlier of (i) the date when the Company
becomes subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act or (ii) the date when the Company makes a determination that it will cease to rely on the exemption afforded by
Rule 12h-1(f)(1) under the Exchange Act. During such period, an Option and, prior to exercise, the Shares to be issued upon exercise of such Option shall be restricted as to any pledge, hypothecation or
other transfer by the Optionee, including any short position, any “put equivalent position” (as defined in Rule 16a-1(h) under the Exchange Act) or any “call equivalent position” (as
defined in Rule 16a-1(b) under the Exchange Act). 
 (h) Withholding Taxes.
As a condition to the grant or exercise of an Option, the Optionee shall make such arrangements as the Board of Directors may require for the satisfaction of any federal, state, local or foreign withholding tax obligations that may arise in
connection with such grant or exercise. The Optionee shall also make such arrangements as the Board of Directors may require for the satisfaction of any federal, state, local or foreign withholding tax obligations that may arise in connection with
the vesting or transfer of Shares acquired by exercising an Option or any similar event. 
 (i) No Rights as a
Stockholder. An Optionee, or a transferee of an Optionee, shall have no rights as a stockholder with respect to any Shares covered by the Optionee’s Option until such person becomes entitled to receive such Shares by filing a notice
of exercise and paying the Exercise Price pursuant to the terms of such Option. 
 (j) Modification, Extension and Assumption of
Options. Subject to the terms of the Plan, the Board of Directors may modify, extend or assume outstanding Options or may accept the cancellation of outstanding Options (whether granted by the Company or another issuer) in return for the
grant of new Options for the same or a different number of Shares and at the same or a different Exercise Price. The foregoing notwithstanding, no modification of an Option shall, without the consent of the Optionee, impair the Optionee’s
rights or increase the Optionee’s obligations under such Option. 

  
 4 

 (k) Company’s Right to Cancel Certain Options. Any other provision of the
Plan or a Stock Option Agreement notwithstanding, the Company shall have the right at any time to cancel an Option that was not granted in compliance with Rule 701 under the Securities Act. Prior to canceling such Option, the Company shall give
the Optionee not less than 30 days’ notice in writing. If the Company elects to cancel such Option, it shall deliver to the Optionee consideration with an aggregate Fair Market Value equal to the excess (if any) of (i) the Fair Market
Value of the Shares subject to such Option as of the time of the cancellation over (ii) the Exercise Price of such Option. The consideration may be delivered in the form of cash or cash equivalents, in the form of Shares, or a combination of
both. For the avoidance of doubt, if the consideration would be a negative amount, such Option may be cancelled without the delivery of any consideration. 

SECTION 7. PAYMENT FOR SHARES. 

(a) General Rule. The entire Purchase Price or Exercise Price of Shares issued under the Plan shall be payable in cash or
cash equivalents at the time when such Shares are purchased, except as otherwise provided in this Section 7. 
 (b) Services
Rendered. At the discretion of the Board of Directors, Shares may be awarded under the Plan in consideration of services rendered to the Company, a Parent or a Subsidiary prior to the award. 

(c) Promissory Note. At the discretion of the Board of Directors, all or a portion of the Purchase Price or Exercise Price
(as the case may be) of Shares issued under the Plan may be paid with a full-recourse promissory note. The Shares shall be pledged as security for payment of the principal amount of the promissory note and interest thereon. The interest rate payable
under the terms of the promissory note shall not be less than the minimum rate (if any) required to avoid the imputation of additional interest under the Code. Subject to the foregoing, the Board of Directors (at its sole discretion) shall specify
the term, interest rate, amortization requirements (if any) and other provisions of such note. 
 (d) Surrender of
Stock. At the discretion of the Board of Directors, all or any part of the Exercise Price may be paid by surrendering, or attesting to the ownership of, Shares that are already owned by the Optionee. Such Shares shall be surrendered to
the Company in good form for transfer and shall be valued at their Fair Market Value as of the date when the Option is exercised. 

(e) Exercise/Sale. To the extent that a Stock Option Agreement so provides, and if Stock is publicly traded, all or part
of the Exercise Price and any withholding taxes may be paid by the delivery (on a form prescribed by the Company) of an irrevocable direction to a securities broker approved by the Company to sell Shares and to deliver all or part of the sales
proceeds to the Company. 
 (f) Other Forms of Payment. To the extent that a Stock Purchase Agreement or Stock Option
Agreement so provides, the Purchase Price or Exercise Price of Shares issued under the Plan may be paid in any other form permitted by the Delaware General Corporation Law, as amended. 

  
 5 

 SECTION 8. ADJUSTMENT OF SHARES. 

(a) General. In the event of a subdivision of the outstanding Stock, a declaration of a dividend payable in Shares, a
combination or consolidation of the outstanding Stock into a lesser number of Shares, a reclassification, or any other increase or decrease in the number of issued shares of Stock effected without receipt of consideration by the Company,
proportionate adjustments shall automatically be made in each of (i) the number of Shares available for future grants under Section 4, (ii) the number of Shares covered by each outstanding Option and (iii) the Exercise Price
under each outstanding Option. In the event of a declaration of an extraordinary dividend payable in a form other than Shares in an amount that has a material effect on the Fair Market Value of the Stock, a recapitalization, a spin-off, or a similar occurrence, the Board of Directors at its sole discretion may make appropriate adjustments in one or more of (i) the number of Shares available for future grants under Section 4,
(ii) the number of Shares covered by each outstanding Option or (iii) the Exercise Price under each outstanding Option. 
 (b)
Mergers and Consolidations. In the event that the Company is a party to a merger or consolidation, outstanding Options and Shares acquired under the Plan shall be subject to the agreement of merger or consolidation, which need not treat all
outstanding Options in an identical manner. Such agreement, without the Optionees’ consent, may dispose of Options that are not exercisable as of the effective date of such merger or consolidation in any manner permitted by applicable law,
including (without limitation) the cancellation of such Options without the payment of any consideration. Such agreement, without the Optionees’ consent, shall provide for one or more of the following with respect to Options that are
exercisable as of the effective date of such merger or consolidation: 
 (i) The continuation of such Options by the Company
(if the Company is the surviving corporation). 
 (ii) The assumption of such Options by the surviving corporation or its
parent in a manner that complies with Section 424(a) of the Code (whether or not such Options are ISOs). 
 (iii) The
substitution by the surviving corporation or its parent of new options for such Options in a manner that complies with Section 424(a) of the Code (whether or not such Options are ISOs). 

(iv) The cancellation of such Options and a payment to the Optionees equal to the excess (if any) of (A) the Fair Market
Value of the Shares subject to such Options as of the effective date of such merger or consolidation over (B) the Exercise Price of such Options. Such payment shall be made in the form of cash, cash equivalents, or securities of the surviving
corporation or its parent with a Fair Market Value equal to the required amount. 
 (v) The cancellation of such Options
without the payment of any consideration. Any exercise of such Options prior to the closing date of such merger or consolidation may be contingent on the closing of such merger or consolidation. 

  
 6 

 (c) Reservation of Rights. Except as provided in this Section 8, a Grantee,
Purchaser or Optionee shall have no rights by reason of (i) any subdivision or consolidation of shares of stock of any class, (ii) the payment of any dividend or (iii) any other increase or decrease in the number of shares of stock of
any class. Any issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number or Exercise Price of
Shares subject to an Option. The grant of an Option pursuant to the Plan shall not affect in any way the right or power of the Company to make adjustments, reclassifications, reorganizations or changes of its capital or business structure, to merge
or consolidate or to dissolve, liquidate, sell or transfer all or any part of its business or assets. 
 SECTION 9.
PRE-EXERCISE INFORMATION REQUIREMENT. 
 (a) Application of Requirement. This
Section 9 shall apply only during a period that (i) commences when the Company begins to rely on the exemption described in Rule 12h-1(f)(1) under the Exchange Act, as determined by the Company
in its sole discretion, and (ii) ends on the earlier of (A) the date when the Company ceases to rely on such exemption, as determined by the Company in its sole discretion, or (B) the date when the Company becomes subject to the
reporting requirements of Section 13 or 15(d) of the Exchange Act. In addition, this Section 9 shall in no event apply to an Optionee after he or she has fully exercised all of his or her Options. 

(b) Scope of Requirement. The Company shall provide to each Optionee the information described in Rule 701(e)(3), (4) and (5)
under the Securities Act. Such information shall be provided at six-month intervals, and the financial statements included in such information shall not be more than 180 days old. The foregoing
notwithstanding, the Company shall not be required to provide such information unless the Optionee has agreed in writing, on a form prescribed by the Company, to keep such information confidential. 

SECTION 10. MISCELLANEOUS PROVISIONS. 

(a) Securities Law Requirements. Shares shall not be issued under the Plan unless the issuance and delivery of such Shares comply with
(or are exempt from) all applicable requirements of law, including (without limitation) the Securities Act, the rules and regulations promulgated thereunder, state securities laws and regulations, and the regulations of any stock exchange or other
securities market on which the Company’s securities may then be traded. The Company shall not be liable for a failure to issue Shares that is attributable to such requirements. 

(b) No Retention Rights. Nothing in the Plan or in any right or Option granted under the Plan shall confer upon the Grantee, Purchaser
or Optionee any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any Parent or Subsidiary employing or retaining the Grantee, Purchaser or Optionee) or
of the Grantee, Purchaser or Optionee, which rights are hereby expressly reserved by each, to terminate his or her Service at any time and for any reason or no reason, with or without cause. 

  
 7 

 (c) Treatment as Compensation. Any compensation that an individual earns or is deemed
to earn under this Plan shall not be considered a part of his or her compensation for purposes of calculating contributions, accruals or benefits under any other plan or program that is maintained or funded by the Company, a Parent or a Subsidiary.

 (d) Governing Law. The Plan and all awards, sales and grants under the Plan shall be governed by, and construed in accordance with,
the laws of the State of Delaware, as such laws are applied to contracts entered into and performed in such State. 
 SECTION 11. DURATION AND
AMENDMENTS. 
 (a) Term of the Plan. The Plan, as set forth herein, shall become effective on the date of its
adoption by the Board of Directors, subject to the approval of the Company’s stockholders. If the stockholders fail to approve the Plan within 12 months after its adoption by the Board of Directors, then any grants, exercises or sales that have
already occurred under the Plan shall be rescinded and no additional grants, exercises or sales shall thereafter be made under the Plan. The Plan shall terminate automatically 10 years after the later of (i) the date when the Board of Directors
adopted the Plan or (ii) the date when the Board of Directors approved the most recent increase in the number of Shares reserved under Section 4 that was also approved by the Company’s stockholders. The Plan may be terminated on any
earlier date pursuant to Subsection (b) below. 
 (b) Right to Amend or Terminate the Plan. The Board of Directors
may amend, suspend or terminate the Plan at any time and for any reason; provided, however, that any amendment of the Plan shall be subject to the approval of the Company’s stockholders if it (i) increases the number of Shares available
for issuance under the Plan (except as provided in Section 8) or (ii) materially changes the class of persons who are eligible for the grant of ISOs. Stockholder approval shall not be required for any other amendment of the Plan. If the
stockholders fail to approve an increase in the number of Shares reserved under Section 4 within 12 months after its adoption by the Board of Directors, then any grants, exercises or sales that have already occurred in reliance on such increase
shall be rescinded and no additional grants, exercises or sales shall thereafter be made in reliance on such increase. 
 (c)
Effect of Amendment or Termination. No Shares shall be issued or sold under the Plan after the termination thereof, except upon exercise of an Option (or any other right to purchase Shares) granted under the Plan prior to such
termination. The termination of the Plan, or any amendment thereof, shall not affect any Share previously issued or any Option previously granted under the Plan. 

SECTION 12. DEFINITIONS. 
 (a)
“Board of Directors” shall mean the Board of Directors of the Company, as constituted from time to time. 

  
 8 

 (b) “Code” shall mean the Internal Revenue Code of 1986, as amended. 

(c) “Committee” shall mean a committee of the Board of Directors, as described in Section 2(a). 

(d) “Company” shall mean Schrödinger, Inc., a Delaware corporation. 

(e) “Consultant” shall mean a person who performs bona fide services for the Company, a Parent or a Subsidiary as a consultant
or advisor, excluding Employees and Outside Directors. 
 (f) “Date of Grant” shall mean the date of grant specified in the
applicable Stock Option Agreement, which date shall be the later of (i) the date on which the Board of Directors resolved to grant the Option or (ii) the first day of the Optionee’s Service. 

(g) “Employee” shall mean any individual who is a common-law employee of the Company,
a Parent or a Subsidiary. 
 (h) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. 

(i) “Exercise Price” shall mean the amount for which one Share may be purchased upon exercise of an Option, as specified by
the Board of Directors in the applicable Stock Option Agreement. 
 (j) “Fair Market Value” shall mean the fair market value
of a Share, as determined by the Board of Directors in good faith. Such determination shall be conclusive and binding on all persons. 
 (k)
“Family Member” shall mean (i) any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew,
mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law, including adoptive relationships, (ii) any person sharing the Optionee’s household (other than a tenant or employee), (iii) a trust in which
persons described in Clause (i) or (ii) have more than 50% of the beneficial interest, (iv) a foundation in which persons described in Clause (i) or (ii) or the Optionee control the management of assets and (v) any
other entity in which persons described in Clause (i) or (ii) or the Optionee own more than 50% of the voting interests. 
 (l)
“Grantee” shall mean a person to whom the Board of Directors has awarded Shares under the Plan. 
 (m)
“ISO” shall mean an employee incentive stock option described in Section 422(b) of the Code. 
 (n)
“Nonstatutory Option” shall mean a stock option not described in Sections 422(b) or 423(b) of the Code. 

  
 9 

 (o) “Option” shall mean an ISO or Nonstatutory Option granted under the
Plan and entitling the holder to purchase Shares. 
 (p) “Optionee” shall mean a person who holds an Option. 

(q) “Outside Director” shall mean a member of the Board of Directors who is not an Employee. 

(r) “Parent” shall mean any corporation (other than the Company) in an unbroken chain of corporations ending with the Company,
if each of the corporations other than the Company owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. A corporation that attains the status of a Parent on a
date after the adoption of the Plan shall be considered a Parent commencing as of the date of attaining such status. 
 (s)
“Plan” shall mean this Schrödinger, Inc. 2010 Stock Plan. 
 (t) “Purchase Price” shall mean the
consideration for which one Share may be acquired under the Plan (other than upon exercise of an Option), as specified by the Board of Directors. 

(u) “Purchaser” shall mean a person to whom the Board of Directors has offered the right to purchase Shares under the Plan
(other than upon exercise of an Option). 
 (v) “Securities Act” shall mean the Securities Act of 1933, as amended. 

(w) “Service” shall mean service as an Employee, Outside Director or Consultant. 

(x) “Share” shall mean one share of Stock, as adjusted in accordance with Section 8 (if applicable). 

(y) “Stock” shall mean the Common Stock of the Company. 

(z) “Stock Grant Agreement” shall mean the agreement between the Company and a Grantee who is awarded Shares under the Plan
that contains the terms, conditions and restrictions pertaining to the award of such Shares. 
 (aa) “Stock Option
Agreement” shall mean the agreement between the Company and an Optionee that contains the terms, conditions and restrictions pertaining to the Optionee’s Option. 

(bb) “Stock Purchase Agreement” shall mean the agreement between the Company and a Purchaser who purchases Shares under the
Plan that contains the terms, conditions and restrictions pertaining to the purchase of such Shares. 

  
 10 

 (cc) “Subsidiary” shall mean any corporation (other than the Company) in an
unbroken chain of corporations beginning with the Company, if each of the corporations other than the last corporation in the unbroken chain owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the
other corporations in such chain. A corporation that attains the status of a Subsidiary on a date after the adoption of the Plan shall be considered a Subsidiary commencing as of the date of attaining such status. 

  
 11 

 EXHIBIT A 

SCHEDULE OF SHARES RESERVED FOR ISSUANCE
UNDER THE PLAN 
  

							
	 Date of Board

Approval
	  	Date of Stockholder Approval	  	Number of
Shares Added	  	Cumulative Number of Shares
	 October 28, 2010
	  	November 12, 2010	  	Not Applicable	  	3,160,000
	 December 6, 2011
	  	December 13, 2011	  	5,000,000	  	8,160,000
	 April 24, 2012
	  	April 24, 2012	  	11,000,000	  	19,160,000
	 November 19, 2012
	  	December 11, 2012	  	3,500,000	  	22,660,000
	 March 8, 2016
	  	March 29, 2016	  	5,000,000	  	27,660,000
	 March 15, 2017
	  	April 3, 2017	  	10,000,000	  	37,660,000
	 November 4, 2017
	  	November 16, 2017	  	3,400,000	  	41,060,000
	 November 9, 2018
	  	November 9, 2018	  	11,000,000	  	52,060,000

  
 A-1 

 EXHIBIT B 

SUB-PLAN FOR CALIFORNIA
RESIDENTS 
 This Exhibit B to the Schrödinger, Inc. 2010 Stock Plan (the “Plan”) will apply only to an award or sale of
Shares or Option granted under the Plan to persons who are residents of the State of California. Capitalized terms contained herein will have the same meanings given to them in the Plan, unless otherwise provided in this Exhibit B.
Notwithstanding any provisions contained in the Plan to the contrary and to the extent required by Section 25102(o) of the California Corporations Code and the regulations promulgated thereunder (“25102(o)”), the following terms will
apply to all awards or sales of Shares and Options granted to residents of the State of California, until such time as the Board of Directors amends this Exhibit B or the Board of Directors otherwise provides. This Exhibit B shall be deemed a part
of the Plan and may be amended by the Board of Directors in accordance with Section 11(b) of the Plan. 
  

	1.	 New Sections 6(l), (m) and (n) of the Plan shall provide: 

“6(l) Termination of Service (Except by Death). If an Optionee’s Service terminates for any reason other than the
Optionee’s death, then the Optionee’s Options shall expire on the earliest of the following dates: 
 (i) The
expiration date determined pursuant to Subsection (e) above; 
 (ii) The date three months after the termination of the
Optionee’s Service for any reason other than Disability, or such earlier or later date as the Board of Directors may determine (but in no event earlier than 30 days after the termination of the Optionee’s Service); or 

(iii) The date six months after the termination of the Optionee’s Service by reason of Disability, or such later date as
the Board of Directors may determine. 
 The Optionee may exercise all or part of the Optionee’s Options at any time before the expiration of such
Options pursuant to the preceding sentence, but only to the extent that such Options had become exercisable before the Optionee’s Service terminated (or became exercisable as a result of the termination) and the underlying Shares had vested
before the Optionee’s Service terminated (or vested as a result of the termination). The balance of such Options shall lapse when the Optionee’s Service terminates. In the event that the Optionee dies after the termination of the
Optionee’s Service but before the expiration of the Optionee’s Options, all or part of such Options may be exercised (prior to expiration) by the executors or administrators of the Optionee’s estate or by any person who has acquired
such Options directly from the Optionee by beneficiary designation, bequest or inheritance, but only to the extent that such Options had become exercisable before the Optionee’s Service terminated (or became exercisable as a result of the
termination) and the underlying Shares had vested before the Optionee’s Service terminated (or vested as a result of the termination). 

  
 B-1 

 6(m) Leaves of Absence. For purposes of Subsection (l) above, Service shall be
deemed to continue while the Optionee is on a bona fide leave of absence, if such leave was approved by the Company in writing and if continued crediting of Service for this purpose is expressly required by the terms of such leave or by applicable
law (as determined by the Company). 
 6(n) Death of Optionee. If an Optionee dies while the Optionee is in Service, then the
Optionee’s Options shall expire on the earlier of the following dates: 
 (i) The expiration date determined pursuant to
Subsection (e) above; or 
 (ii) The date 12 months after the Optionee’s death, or such earlier or later date as
the Board of Directors may determine (but in no event earlier than six months after the Optionee’s death). 
 All or part of the Optionee’s
Options may be exercised at any time before the expiration of such Options under the preceding sentence by the executors or administrators of the Optionee’s estate or by any person who has acquired such Options directly from the Optionee by
beneficiary designation, bequest or inheritance, but only to the extent that such Options had become exercisable before the Optionee’s death (or became exercisable as a result of the death) and the underlying Shares had vested before the
Optionee’s death (or vested as a result of the Optionee’s death). The balance of such Options shall lapse when the Optionee dies.” 
 1.
The following language shall be added to the end of Section 8(a) of the Plan: 
 “; provided, however, that
the Board of Directors shall in any event make such adjustments as may be required by Section 25102(o) of the California Corporations Code.” 
  

	2.	 New Section 12(dd) shall be added to the Plan: 

“12(dd) “Disability” shall mean that the Optionee is unable to engage in any substantial gainful activity by reason of
any medically determinable physical or mental impairment.” 

  
 B-2 

 EXHIBIT C 

SUB-PLAN FOR RESIDENTS OF
INDIA 
 (the “Sub-Plan”) 

Additional Terms and Conditions for Options received by Optionees resident in India: 
  

	 	1.	 The purpose of this Sub-Plan is to provide incentives for present and
future Indian resident employees of Schrödinger, Inc. and any Subsidiary through the grant of options over shares of the Common Stock of Schrödinger, Inc. (the “Company”). 

 

	 	2.	 Capitalized terms are defined in the Schrödinger, Inc. 2010 Stock Plan (the “Plan”), subject to
the provisions of this Sub-Plan. 

  

	 	3.	 This Sub-Plan is governed by the Plan and all its provisions shall be
identical to those of the Plan SAVE THAT (i) “Sub-Plan” shall be substituted for “Plan” where applicable and (ii) the following provisions shall be included in this Sub-Plan as set forth below in order to accommodate the specific requirements of the laws of India: 

SECTION 3. Eligibility. 

Section 3(a), General Rule, shall be replaced with the following: 

“Only Employees who are resident in India shall be eligible to be granted Options under this
Sub-Plan. For the avoidance of doubt, Consultants and Outside Directors who are resident in India shall not be eligible to be granted Options under this Sub-Plan.”

 SECTION 12. Definitions. 

The following definition shall be amended to read as follows: 

“(g) ‘Employee’ shall mean any individual who (1) is a common-law employee
of an Indian Subsidiary; or (2) carries out his or her day to day employment duties at an Indian branch office of such individual’s employer company, such employer company being the Company, a Parent or a Subsidiary.” 

SECTION 7. Payment of Shares. 

Section 7(a) shall be amended to read as follows: 

“(a) General Rule. The entire Purchase Price or Exercise Price of Shares issued under the Plan shall be payable in cash at the time
when such Shares are purchased, except as otherwise provided in this Section 7.” 
 Section 7(b) is deleted. 

Section 7(c) is deleted. 

  
 C-1 

 EXHIBIT D 

IRISH SUPPLEMENT 

Capitalized terms not explicitly defined in this Irish Supplement but defined in the Plan shall have the same definitions as in the Plan, unless the context
otherwise requires. 
  

	1.	 Purpose and eligibility 

The purpose of this supplement to the Plan (the “Irish Supplement”) is to enable the Board of Directors to grant awards,
including any Options, Shares, other Stock-based award or any combination of the foregoing, (the “Award” or “Awards”), to certain Employees, Outside Directors and Consultants of the Company, a Parent, a Subsidiary
or a related company (the “Group”) who are based in Ireland. The Irish Supplement should be read and construed as one document with the Plan. Awards (which in the case of Options will be unapproved for Irish tax purposes) may only
be granted under the Irish Supplement to Employees, Outside Directors and Consultants of the Group. Any person to whom an Award has been granted under the Irish Supplement is the Grantee, Optionee or Purchaser (hereinafter the
“Participant”) for the purposes of the Plan. 
 The tax and social security consequences of participating in the Plan are
based on complex tax and social security laws, which may be subject to varying interpretations, and the application of such laws may depend, in large part, on the surrounding facts and circumstances. Therefore, we recommend that the
Participant consults with their own tax advisor regularly to determine the consequences of taking or not taking any action concerning their participation in the Plan and to determine how the tax, social security or other laws in Ireland (or
elsewhere) apply to their specific situation. 
  

	2.	 Terms 

Awards granted pursuant to the Plan shall be governed by the terms of the Plan, subject to any such amendments set out herein and as are
necessary to give effect to Section 1 of the Irish Supplement, and by the terms of the individual Stock Grant Agreement, Stock Option Agreement or Stock Purchase Agreement (the “Stock Agreement”) entered into between the
Company and the Participant. To the extent that there is a conflict between the rules of the Plan and the Irish Supplement or the Stock Agreement and the Irish Supplement, the provisions of the Irish Supplement shall prevail. 

 

	3.	 Taxes 

The references in the Plan and / or the Stock Agreement to “Withholding Taxes” includes any and all taxes, charges, levies and
contributions in Ireland or elsewhere, to include, in particular, Universal Social Charge (USC) and Pay Related Social Insurance (PRSI) (“Taxes”). 

  
 D-1 

	4.	 Tax indemnity 

 

	4.1	 The Participant shall be accountable for any Taxes, which are chargeable on any assessable income deriving from
the grant, exercise, purchase, or vesting of, or other dealing in Awards, or Stock issued pursuant to an Award. The Group shall not become liable for any Taxes, as a result of the Participant’s participation in the Plan. In respect of such
assessable income, the Participant shall indemnify the Company and (at the direction of the Company) any entity of the Group, which is or may be treated as the employer of the Participant in respect of the Taxes (the “Tax
Liabilities”). 

  

	4.2	 Pursuant to the indemnity referred to in Section 4.1, where necessary, the Participant shall make such
arrangements, as the Group requires to meet the cost of the Tax Liabilities, including at the direction of the Company any of the following: 

  

	 	(a)	 making a cash payment of an appropriate amount to the relevant Group company whether by cheque, banker’s
draft or deduction from salary in time to enable the Group to remit such amount to the Irish Revenue Commissioners before the 14th day following the end of the month in which the event giving rise to the Tax Liabilities occurred; or

  

	 	(b)	 appointing the Company as agent and / or attorney for the sale of sufficient shares of Stock acquired pursuant
to the grant, exercise, purchase or vesting of, or other dealing in Awards, or Stock issued pursuant to an Award to cover the Tax Liabilities and authorising the payment to the relevant Group company of the appropriate amount (including all
reasonable fees, commissions and expenses incurred by the relevant company in relation to such sale) out of the net proceeds of sale of the shares of Stock. 

  

	5.	 Employment rights 

 

	5.1	 The Participant acknowledges that his or her terms of employment shall not be affected in any way by his or her
participation in the Plan which shall not form part of such terms (either expressly or impliedly). The Participant acknowledges that his or her participation in the Plan shall be subject at all times to the rules of the Plan as may be amended from
time to time (including, but not limited to, any clawback provisions). If on termination of the Participant’s employment (whether lawfully, unlawfully, or in breach of contract) he or she loses any rights or benefits under the Plan (including
any rights or benefits which he or she would not have lost had his or her employment not been terminated), the Participant hereby acknowledges that he or she shall not be entitled to (and hereby waives) any compensation for the loss of any rights or
benefits under the Plan, or any replacement or successor plan. 

  

	5.2	 The Plan is entirely discretionary and may be suspended or terminated by the Board of Directors at any time for
any reason. Participation in the Plan is entirely discretionary and does not create any contractual or other right to receive future grants of Awards, or benefits in lieu of Awards. All determinations with respect to future grants will be at the
sole discretion of the Board of Directors. Rights under the Plan are not pensionable. 

  
 D-2 

	6.	 Data Protection 

 

	6.1	 The Participant understands and acknowledges that the Company will collect, use, disclose, transfer and
otherwise process in electronic or other form, any personal data (the “Data”) regarding the Participant’s employment, the nature of the Participant’s salary and benefits and the details of the Participant’s participation in
the Plan, including but not limited to, the Participant’s home address, telephone number, date of birth, personal public service number, salary, nationality, job title, entitlements under an Award, and number of shares of Stock, which were
granted, exercised, purchased, vested or dealt with under an Award, or issued pursuant to an Award. The Company will use the Data to the extent necessary (i) for the purposes of performing the contract with the Participant, namely, for the
purposes of implementing, administering and managing the Participant’s participation in the Plan and complying with terms of Stock Agreement, (ii) for compliance with the Company’s legal obligations, including compliance with
applicable tax and regulatory reporting obligations or (iii) for legitimate interests of the Company, including board and group reporting and management purposes, in connection with group reorganisations or divestments, and / or to take advice
from its external legal and other advisors; and (iv) where the Participant has otherwise consented to the Company using the Data for a particular purpose. 

 

	6.2	 In connection with such purposes, the Company may obtain the Data from the Participant’s employer within
the Group and may disclose and transfer Data (i) to any entity within the Group and to any carefully selected third party involved with the implementation, administration and management of the Plan, including any requisite transfer to a broker
or other third party assisting with the grant, exercise, purchase or vesting of, or dealing with Awards or Stock issued pursuant to an Award, or with whom the Shares may be deposited, (ii) to its auditors, and legal and other advisors and / or
(iii) if the disclosure is required by law or regulation, or court or administrative order having force of law. The Participant understands and acknowledges that the transfer of Data to such third parties may be necessary to facilitate the
Participant’s participation in the Plan and for the purposes of complying with the terms of the Stock Agreement. 

  

	6.3	 The Participant understands and acknowledges that the Data may be transferred outside of the European Economic
Area (the “EEA”) in connection with implementing, administering and managing the Participant’s participation in the Plan and / or otherwise required or permitted by applicable law. The Participant further understands that many
of the countries will be within the EEA, or will be ones which the European Commission has approved, and will have data protection laws which are the same or broadly equivalent to those in Ireland and other European Countries. However, some
transfers may be to countries which do not have equivalent protections, and in that case the Company shall use reasonable efforts to implement contractual protections for the Data. While this will not always be possible where the Company is required
to transfer the Data in order to comply with and perform the contract with the Participant or where it has a legal obligation to do so, any transfers will be done in accordance with applicable data protection laws, including through the
implementation of appropriate or suitable safeguards in accordance with such applicable data protection laws. For the avoidance of doubt, safeguards in the form of EU Commission approved standard contractual clauses will be implemented and executed
by the Company and the relevant third party. 

  
 D-3 

	6.4	 The Company is obliged to retain certain information to ensure accuracy, to implement, administer and manage
the Participant’s participation in the Plan, and for legal and regulatory purposes and for the performance of the contract with the Participant. Data will be retained for no longer than is necessary for the purpose for which it was obtained by
the Company or as is required or permitted for legal or regulatory purposes. In general, the Company (or its service providers on its behalf) will hold the Data for a period of seven years, unless it is obliged to hold it for a longer period under
law or applicable regulations. 

  

	6.5	 Additional information regarding the Group’s data protection practices and the Participant’s specific
rights in relation to the processing of his/her Data (including the relevant Company contact details in respect of any questions or complaints the Participant may have) are set out in the Group’s data protection policy, which is available to
all Participants on the Company’s intranet. 

  
 D-4 

 EXHIBIT E 

UK SUB-PLAN 

Neither this document, nor any stock option agreement connected with it, is an approved prospectus for the purposes of section 85(1) of the Financial
Services and Markets Act 2000 (“FSMA”) and no offer of transferable securities to the public (for the purposes of section 102B of FSMA) is being made in connection with the UK Sub-Plan to the
Schrödinger, Inc. 2010 UK Stock Plan (the “Sub-Plan”). The Sub-Plan is exclusively available to bona fide employees and former employees of
Schrödinger, Inc, and any UK Subsidiary which may be set up. 
 UK SUB-PLAN TO THE

 SCHRÖDINGER, INC. 

2010 STOCK PLAN 
 Additional Terms and
Conditions for Options received by Optionees resident in the UK 
  

	1.	 The purpose of this Sub-Plan is to provide incentives for present and
future UK tax resident employees of Schrödinger, Inc and any UK Subsidiary which may be set up through the grant of options over shares of Common Stock of Schrödinger, Inc (the “Company”). 

 

	2.	 Capitalized terms are defined in the Plan, subject to the provisions of this
Sub-Plan. 

  

	3.	 References to Incentive Stock Options and Nonstatutory Stock Options shall not apply to Options granted under
the Sub-Plan. 

  

	4.	 The Options granted under this Sub-Plan shall be designated as
Unapproved Options. 

  

	5.	 This Sub-Plan is governed by the Company’s 2010 Stock Plan (the
“Plan”) and all its provisions shall be identical to those of the Plan SAVE THAT (i) “Sub-Plan” shall be substituted for “Plan” where applicable and (ii) the following
provisions shall be as stated in this Sub-Plan in order to accommodate the specific requirements of the laws of England and Wales: 

 

	6.	 SECTION 1. ESTABLISHMENT AND PURPOSE. 

The first paragraph of this Section shall be replaced with the following paragraph: 

“The purpose of the Plan is to offer selected persons an opportunity to acquire a proprietary interest in the success of the Company, or
to increase such interest, by acquiring Shares of the Company’s Stock. The Plan provides for the grant of Options to purchase Shares. Options granted under the Plan shall be Unapproved Options.” 

 

	7.	 SECTION 2. ADMINISTRATION. 

This Section shall be deleted and replaced with the following words: 

  
 E-1 

 “(a) General Rule. Only Employees shall be eligible for the grant of
Options.” 
  

	8.	 SECTION 4. STOCK SUBJECT TO PLAN. 

This section shall be replaced in its entirety with the following: 

“(a) Basic Limitation. Not more than 37,660,000 Shares may be issued under the Schrodinger, Inc. 2010 Stock Plan (which shall include this
UK Sub-Plan to the Schrodinger, Inc. 2010 Stock Plan), subject to Subsection (b) below and Section 8(a). Any or all of these Shares may be issued upon the exercise of Options. The number of Shares
that are subject to Options or other rights outstanding at any time under the Schrodinger, Inc. 2010 Stock Plan (including this UK Sub-Plan to the Schrodinger, Inc. 2010 Stock Plan) shall not exceed the number
of Shares that then remain available for issuance under the Schrodinger, Inc. 2010 Stock Plan (including this UK Sub-Plan to the Schrodinger, Inc. 2010 Stock Plan). The Company, during the term of the
Schrodinger, Inc. 2010 Stock Plan, shall at all times reserve and keep available sufficient Shares to satisfy the requirements of the Schrodinger, Inc. 2010 Stock Plan (including this UK Sub-Plan to the
Schrodinger, Inc. 2010 Stock Plan). Shares offered under the Schrodinger, Inc. 2010 Stock Plan (including this UK Sub-Plan to the Schrodinger, Inc. 2010 Stock Plan) may be authorized but unissued Shares or
treasury Shares. 
 (b) Additional Shares. In the event that Shares previously issued under the Schrodinger, Inc. 2010 Stock Plan (which
shall include this UK Sub-Plan to the Schrodinger, Inc. 2010 Stock Plan) are reacquired by the Company, such Shares shall be added to the number of Shares then available for issuance under the Schrodinger,
Inc. 2010 Stock Plan (including this UK Sub-Plan to the Schrodinger, Inc. 2010 Stock Plan). In the event that Shares that otherwise would have been issuable under the Plan are withheld by the Company in
payment of the Exercise Price and any withholding taxes (including any Option Tax Liability and any Secondary NIC Liability), such Shares shall remain available for issuance under the Schrodinger, Inc. 2010 Stock Plan (which shall include this UK Sub-Plan to the Schrodinger, Inc. 2010 Stock Plan). In the event that an outstanding Option or other right for any reason expires or is cancelled, the Shares allocable to the unexercised portion of such Option or
other right shall be added to the number of Shares then available for issuance under the Schrodinger, Inc. 2010 Stock Plan (including this UK Sub-Plan to the Schrodinger, Inc. 2010 Stock Plan).” 

 

	9.	 SECTION 5. TERMS AND CONDITIONS OF AWARDS OR SALES. 

This Section shall be deleted. 
  

	10.	 SECTION 6. TERMS AND CONDITIONS OF OPTIONS. 

(b) Number of Shares. 
 The
final sentence of this Sub-Section shall be deleted. 

  
 E-2 

 (c) Exercise Price. 

The words “and in the case of an ISO a higher percentage may be required by Section 3(b)” and the words “(whether or not
the Option is an ISO)” shall be deleted. 
 (d) Exercisability. 

The words “the Joint Election and the Section 431 Election” shall be inserted immediately before the words “to the
Company” and the words “and delivers signed copies of the Joint Election and the Section 431 Election to the Company” shall be inserted after the words “the terms of the Stock Option Agreement”. 

(e) Term. 
 The words
“, and in the case of an ISO a shorter term may be required by Section 3(b)” shall be deleted. 
 (g) Pre-Exercise Restrictions on Transfer of Options or Shares. 
 The second sentence shall be replaced
with the following words: 
 “An Option shall be transferable by the Optionee only on the Optionee’s death to the Optionee’s
Personal Representative”. 
 (h) Withholding Taxes. 

This Sub-Section shall be replaced with the following words: 

“In the event that the Company or any Subsidiary determines that it is required to account (or pay) to HM Revenue & Customs for
any Option Tax Liability or Secondary NIC Liability (under the Stock Option Agreement) arising from the grant, exercise, assignment, release, cancellation or any other disposal of an Option or arising out of the acquisition, retention and disposal
of the Shares acquired pursuant to the Option, the Optionee, as a condition to the issue of Shares in connection with the exercise of an Option, or on the grant, assignment, release or cancellation of an Option, shall make such arrangements
satisfactory to the Company to enable it or any Subsidiary to satisfy any requirement to account for any Option Tax Liability (and, if applicable, any Secondary NIC Liability) that may arise in connection with the Option or the award of Shares
pursuant to it including, but not limited to, arrangements satisfactory to the Company for withholding Stock that would otherwise be issued pursuant to the Stock Option Agreement to the Optionee.” 

(k) Company’s Right to Cancel Certain Options. 

The words “cash equivalents, in the form of Shares” shall be replaced with the words “by cheque”. 

 

	11.	 SECTION 7. PAYMENT FOR SHARES. 

The words “Purchase Price or” shall be deleted. 

  
 E-3 

 The words “cash equivalents” shall be replaced with the words “by
cheque”. 
 (b) Services Rendered; (c) Promissory Note; (d) Surrender of Stock; (f) Other Forms
of Payment. 
 These Sub-Sections shall be deleted. 

 

	12.	 SECTION 8. ADJUSTMENT OF SHARES. 

(b) Mergers and Consolidations. 

The words “(whether or not such Options are ISOs)” shall be deleted wherever they appear. 

The words “cash equivalents” shall be replaced by the words “by cheque”. 

(c) Reservation of Rights. 

The words “a Grantee, a Purchaser or” shall be replaced with the word “an”. 

 

	13.	 SECTION 9. MISCELLANEOUS PROVISIONS. 

(b) No Retention Rights. 

The words “Grantee, Purchaser, or” shall be deleted wherever they appear. 

(d) Governing Law. 
 The
following words shall be inserted at the end of this Sub-Section: 
 “The Joint Election and the
Section 431 Election shall be governed by the laws of England and Wales.” 
  

	14.	 SECTION 11. DURATION AND AMENDMENTS. 

(a) Term of the Plan. 

This Sub-Section shall be replaced with the following paragraph: 

“The Plan, as set forth herein, shall become effective on the date of its adoption by the Board of Directors. The Plan shall terminate
automatically on the termination of the Schrödinger, Inc. 2010 Stock Plan. The Plan may be terminated on any earlier date pursuant to Subsection (b) below.” 

(b) Right to Amend or Terminate the Plan. 

This Sub-Section shall be replaced with the following paragraph: 

  
 E-4 

 “The Board of Directors may amend, suspend or terminate the Plan at any time and for
any reason subject to any applicable laws.” 
 (c) Effect of Amendment or Termination. 

The words “(or any other right to purchase Shares)” shall be deleted. 

 

	15.	 SECTION 12. DEFINITIONS. 

The following Definitions shall be amended: 

(f) “Date of Grant” shall mean the date of grant specified in the applicable Stock Option Agreement. 

(g) “Employee” shall mean any individual who is an employee of the Company, a Parent or a Subsidiary. 

(o) “Option” shall mean an Unapproved Option granted under the Plan and entitling the holder to purchase Shares. 

(s) “Plan” shall mean the UK Sub-Plan to the Schrödinger, Inc. 2010 Stock Plan.

 (w) “Service” shall mean Service as an Employee. 

The following Definitions shall be deleted: 

(e) “Consultant” 

(l) “Grantee” 

(m) “ISO” 
 (n)
“Nonstatutory Option” 
 (q) “Outside Director” 

(t) “Purchase Price” 

(u) “Purchaser” 

(z) “Stock Grant Agreement” 

(bb) “Stock Purchase Agreement” 

The following definitions shall be inserted: 

(k) “Joint Election” shall mean an election (in such terms and such form as provided in paragraphs 3A and 3B of Schedule 1 to
the Social Security Contributions and Benefits Act 1992), which has been approved by HM Revenue & Customs for the transfer of the whole of any liability of the Secondary Contributor for any Secondary NIC Liability. 

  
 E-5 

 (n) “Option Tax Liability” shall mean any liability or obligation of the
Company and/or any Subsidiary to account (or pay) for income tax (under the UK withholding system of PAYE (pay as you earn)) or any other taxation provisions and primary class 1 National Insurance Contributions in the United Kingdom to the extent
arising from the grant, exercise, assignment, release, cancellation or any other disposal of an Option or arising out of the acquisition, retention and disposal of the Shares acquired under this Plan. 

(p) “Personal Representative” shall mean the personal representative(s) of an Optionee (being either the executors of his will
or if he dies intestate the duly appointed administrator(s) of his estate) who have provided to the Board evidence of their appointment as such. 

(r) “Secondary Contributor” shall mean a person or company who has a liability to account (or pay) the Secondary NIC Liability
to HMRC. 
 (s) “Secondary NIC Liability” shall mean any liability to employer’s Class 1 National Insurance
Contributions to the extent arising from the grant, exercise, release or cancellation of an Option or arising out of the acquisition, retention and disposal of the Shares acquired pursuant to an Option. 

(t) “Section 431 Election” shall mean an election made under section 431 of the Income Tax (Earnings and
Pensions) Act 2003. 
 (aa) “Taxable Event” shall mean any occasion on which an Option Tax Liability or Secondary NIC
Liability arises in connection with an Option or any award of Stock under it. 
 (bb) “UK Subsidiary” shall mean a
Subsidiary of the Company which is incorporated in the UK. 
 (cc) “Unapproved Option” shall mean an Option over Shares in
the Company that is neither an HM Revenue & Customs approved company share option plan nor an EMI Option. 
  

	16.	 Exhibit B shall be deleted. 

  
 E-6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]